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Abstract	  
Colorectal	   cancer	   (CRC)	   is	   the	   second	  most	   common	   cause	   of	   cancer	   related	   death	  
worldwide	   with	   an	   expected	   1.8	   million	   new	   cases	   this	   year	   (1).	   CRC	   claims	  
approximately	  1200	  New	  Zealand	  lives	  per	  year	  and	  rectal	  cancer	  patients	  account	  for	  
approximately	  25%	  of	  CRC	  cases	  (2).	  The	  mainstay	  of	  treatment	  for	   locally	  advanced	  
rectal	   cancer	   is	   neoadjuvant	   therapy	   followed	   by	   surgical	   excision.	   The	   purpose	   of	  
neoadjuvant	   therapy	   is	   to	   reduce	   rates	   of	   local	   recurrence,	   increase	   sphincter	  
preservation	  and	  to	   improve	  tumour	  resectability	  (3),	  however	  the	  risk	  to	  patients	   is	  
exposure	  to	  unnecessary	  toxins	  and	  their	  effects.	  Most	  importantly,	  patient	  response	  
to	  neoadjuvant	  therapy	  is	  varied,	  and	  complete	  pathological	  response	  will	  occur	  in	  15-­‐
27%	  of	  patients	  (4).	  Therefore,	  a	  significant	  proportion	  of	  patients	  undergoing	  therapy	  
will	   suffer	  unnecessary	  delays	   to	   surgery	  and	   toxic	  exposure.	  There	  are	  currently	  no	  
clinically	  utilised	  biomarkers	  to	  predict	  response	  to	  neo-­‐adjuvant	  therapy.	  Development	  
of	  predictive	  markers	  would	  enable	  optimal	  treatment	  of	  patients	  and	  avoid	  ineffective	  
and	  potentially	   harmful	   treatments.	  miRNA	  are	   short	   regulatory	   transcripts	   that	   are	  
stable	  in	  biofluids.	  Their	  dysregulation	  has	  been	  extensively	  reported	  in	  CRC	  and	  their	  
usefulness	   in	   the	   detection	   of	   cancer	   and	   as	   predictors	   of	   prognosis	   and	   treatment	  
response	  is	  a	  rapidly	  growing	  area	  of	  research.	  Whilst	  the	  majority	  of	  work	  has	  been	  on	  
tissue	  biomarkers,	  blood	  biomarkers	  would	  be	  less	  invasive	  and	  expose	  patients	  to	  less	  
risk.	  	  
	  
This	  thesis	  has	  investigated	  changes	  in	  circulating	  miRNA	  levels	   in	  patients	  who	  have	  
locally	  advanced	  rectal	  cancer	  and	  have	  undergone	  neoadjuvant	  therapy.	  The	  main	  aim	  
of	  this	  study	  was	  to	  ascertain	  if	  miR-­‐21,	  miR-­‐29a,	  miR-­‐143,	  and	  miR-­‐145	  levels	  in	  plasma	  
prior	  to	  treatment	  can	  predict	  response	  to	  SCR	  and	  LCCR	  therapy.	  Plasma	  samples	  were	  
taken	  prior	   to	   and	  after	   neoadjuvant	   therapy.	   RNA	  was	  extracted	   and	  miRNA	   levels	  
were	   analysed	   using	   RT-­‐qPCR.	   Relative	   expression	   was	   evaluated	   and	   compared	   to	  
pathological	   specimen	   reports	   after	   surgery.	   In	   this	   pilot	   study	   we	   have	   found	   a	  
significant	  increase	  in	  the	  relative	  expression	  miR-­‐143	  in	  plasma	  after	  SCR.	  There	  was	  
no	  difference	  in	  expression	  of	  miR-­‐21,	  miR-­‐29a,	  miR-­‐143	  or	  miR-­‐145	  in	  patients	  with	  
	   iii	  
stage	  II	  and	  III	  rectal	  cancer	  compared	  to	  healthy	  controls.	  There	  was	  no	  difference	  in	  
expression	  of	   target	  miRNA	   in	  patients	  who	  had	  a	   response	   to	  neoadjuvant	   therapy	  
compared	  to	  those	  who	  did	  not	  respond.	  	  
	  
This	  is	  the	  first	  study	  to	  use	  patients’	  plasma	  to	  evaluate	  the	  expression	  of	  these	  miRNA	  
and	   examine	   whether	   this	   can	   predict	   TRG.	   This	   is	   important	   because	   finding	   a	  
predictive	  blood	  biomarker	   is	   a	  more	  accessible	   and	  potentially	   clinically	  useful	   tool	  
than	  tumour	  biopsy.	  Findings	  from	  this	  study	  will	  contribute	  to	  the	  pool	  of	  research	  on	  
the	  use	  of	  miRNA’s	  in	  CRC	  for	  diagnostic	  and	  predictive	  tests.	  As	  this	  is	  a	  pilot	  study,	  
future	  samples	  being	  collected	  from	  these	  patients	  may	  also	  contribute	  to	  knowledge	  
on	  recurrence.	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Chapter	  1:	  	  
Introduction	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1.1	  Colorectal	  cancer	  
Colorectal	   cancer	   (CRC)	   is	   a	   significant	   problem	  with	   a	   huge	   impact	   on	   health	   both	  
globally	  and	  in	  Australasia.	  Worldwide,	  CRC	  is	  the	  third	  most	  common	  cancer	  and	  the	  
second	  leading	  cause	  of	  cancer	  related	  mortality	  (1).	  New	  Zealand	  and	  Australia	  have	  
the	  second	  highest	  rates	  in	  the	  developed	  world	  (1).	  In	  2013,	  CRC	  was	  the	  second	  most	  
commonly	   diagnosed	   cancer	   in	   both	   men	   and	   women	   in	   New	   Zealand	   with	  
approximately	  3,200	  new	  cases	  registered	  and	  1,200	  deaths	  (2).	  	  
	  
CRC	  places	  a	  high	  demand	  on	  the	  health	  system	  and	  is	  costly.	  Whilst	  the	  rates	  of	  CRC	  
are	  declining,	  the	  actual	  number	  of	  registered	  cases	  are	  on	  the	  rise	  due	  to	  the	  increase	  
in	   the	   New	   Zealand	   population	   and	   the	   increasing	   average	   age	   (5).	   Therefore,	   the	  
number	  of	  CRC	  diagnoses	  is	  expected	  to	  increase	  by	  26%	  by	  the	  year	  2026	  which	  will	  
lead	  to	  an	  increased	  need	  for	  follow	  up	  endoscopy,	  surgery,	  chemotherapy	  and	  clinical	  
follow	  up/surveillance	  (6).	  The	  forecasted	  annual	  costs	  for	  CRC	  is	  projected	  to	  increase	  
from	  $83.6	  million	  in	  2014	  to	  $100	  million	  in	  2026	  (6).	  	  
	  
Whilst	  the	  difference	  between	  colon	  and	  rectal	  cancer	  are	  somewhat	  anatomical,	  the	  
therapeutic	  approaches	  of	  surgery	  and	  chemoradiation	  are	  different.	  For	  this	  reason,	  
we	  must	   consider	   them	   separately.	   The	   PIPER	   Project	   (Jackson	   2015)	   is	   the	   largest	  
national	  CRC	  retrospective	  cohort	  study	  and	  reports	  that	  in	  New	  Zealand	  rectal	  cancer	  
accounts	  for	  around	  25%	  of	  all	  CRC	  cases.	  62%	  of	  patients	  in	  this	  cohort	  were	  male	  and	  
the	  majority	  were	   in	   the	   age	   bracket	   of	   60-­‐80	   years	   old.	  Māori	   and	   Pacific	   patients	  
presented	  with	   higher	   rates	   of	  metastatic	   rectal	   cancer	   than	  non-­‐Māori,	   non-­‐Pacific	  
patients.	  Of	  concern,	   there	  was	  a	  high	  rate	  of	  Emergency	  Department	  presentations	  
(14%),	  and	  a	  high	  proportion	  (19%)	  of	  patients	  presented	  with	   late	  stage,	  metastatic	  
disease	  (7).	  
	  
Despite	  major	  advances	   in	  detection	  and	   treatments	   for	  patients	  with	   rectal	   cancer,	  
there	   is	   still	   a	   lack	  of	  understanding	  as	   to	  which	  patients	  will	  benefit	   the	  most	   from	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which	   treatment.	   Further	   research	   is	   required	   to	   investigate	   how	   we	   can	   tailor	  
treatment	  more	  appropriately	  for	  individual	  patients.	  	  	  	  
	  
1.2	  Presentation	  and	  management	  of	  patients	  with	  rectal	  cancer	  
Patients	  with	  rectal	  cancer	  may	  be	  asymptomatic	  or	  may	  present	  with	  change	  in	  bowel	  
habit,	   loss	  of	  weight,	  tenesmus,	  and	  bleeding	  per	  rectum	  (8).	   In	  some	  cases	  patients	  
may	  only	  have	  iron	  deficiency	  anaemia.	  These	  signs	  and	  symptoms	  can	  be	  nonspecific	  
but	  should	  prompt	  early	  investigation	  of	  the	  colon	  and	  rectum.	  Patients	  in	  New	  Zealand	  
have	   access	   to	   endoscopy	   via	   population	   screening	   through	   the	  Ministry	   of	   Health	  
Bowel	  Cancer	  Screening	  program,	  through	  surveillance	  if	  at	  an	  increased	  risk	  of	  CRC,	  or	  
if	   presenting	   with	   symptoms	   (9).	   Once	   rectal	   cancer	   has	   been	   diagnosed,	   prompt	  
assessment	  of	  stage	  should	  occur	  (9).	  Preoperative	  staging	  should	  consist	  of;	  complete	  
history	   and	   physical	   exam,	   complete	   blood	   count,	   liver	   and	   renal	   function	   tests,	  
carcinoembryonic	   antigen	   (CEA),	   digital	   rectal	   examination	   and	   rigid	   sigmoidoscopy,	  
colonoscopy,	  chest	  abdominal	  and	  pelvic	  computerised	  tomography	  (CT),	  and	  magnetic	  
resonance	  imaging	  (MRI)	  of	  the	  pelvis	  or	  endorectal	  ultrasound	  (9).	  	  
	  
The	  stage	  of	  cancer	  defines	  the	  local	  and	  distant	  extend	  of	  disease	  and	  is	  required	  for	  
guidance	   of	   treatment	   options	   (10).	   The	   most	   widely	   used	   classification	   of	   CRC	  
carcinomas	  is	  the	  tumour,	  nodes	  and	  metastases	  (TNM)	  classification	  (11)	  (Table	  1).	  This	  
is	  based	  on	  the	  local	  depth	  of	  tumour	  invasion	  (T),	  presence	  and	  number	  of	  lymph	  nodes	  
effected	  (N),	  and	  presence	  of	  distant	  metastatic	  disease	  (M)	  (10).	  Lower	  T	  stage	  (T0-­‐2)	  
leads	  to	  statistically	  significant	  decreased	  rates	  of	  local	  recurrence,	  metastatic	  disease	  
free	  survival	  and	  overall	  survival	  (12).	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Table	  1	  Colorectal	  Cancer	  TNM	  Stage	  (AJCC	  7th	  Edition)	  
Stage	   T	   N	   M	  
0	   Tis	   N0	   M0	  
I	   T1/T2	   N0	   M0	  
II	   T3/T4a/T4b	   N0	   M0	  
III	   T1/T2/T3/T4	   N1a/b/c/N2a/b/c	   M0	  
IV	   Any	  T	   Any	  N	   M1a/M1b	  
Tis	  =	  carcinoma	  in	  situ,	  T1	  =	  tumour	  invades	  submucosa,	  T2	  =	  tumour	  invades	  muscularis	  propria,	  
T3	  =	  tumour	  invades	  into	  pericolorectal	  tissues,	  T4	  =	  tumour	  penetrates	  to	  the	  surface	  of	  the	  (a)	  
visceral	  peritoneum	  or	  (b)	  directly	  invades,	  or	  is	  adherent	  to	  other	  organs	  or	  structures,	  	  
N0	  =	  No	  regional	  lymph	  node	  metastasis,	  N1	  =	  Metastasis	  in	  1-­‐3	  lymph	  nodes	  (a=	  1,	  b=	  2-­‐3,	  c	  =	  
no	  lymph	  nodes	  but	  deposits	  in	  subserosa,	  mesentery	  or	  non-­‐peritonalised	  perirectal/mesorectal	  
tissues,	  N2	  =	  metastasis	  in	  4	  or	  more	  regional	  lymph	  nodes	  (a	  =	  4-­‐6,	  b	  =	  7+),	  M0	  =	  no	  distant	  
metastasis,	   M1	   =	   Distant	   metastasis	   (a	   =	   1	   organ	   site,	   b	   =	   2+	   organ	   sites,	   c	   =	   peritoneal	  
metastasis).	  	  
	  
The	  5	  year	  relative	  survival	  rate	  for	  all	  stages	  of	  rectal	  cancer	  has	  improved	  from	  the	  
mid	  1970s	  until	   the	  period	  2006-­‐2012	   from	  48%	  to	  68%,	   reflecting	   improvements	   in	  
detection	   and	   treatment	   (13).	   Five	   year	   survival	   rates	   are	   approximately	   90%	   for	  
localised	  disease,	  70%	  for	  disease	  with	  regional	  spread	  and	  12%	  for	  disease	  with	  distant	  
spread	   (13).	   In	   New	   Zealand,	   76%	   of	   rectal	   cancer	   patients	   present	   with	   stage	   I-­‐III	  
disease	  (non-­‐metastatic)	  (7).	  
	  
Histological	  features	  other	  than	  TNM	  stage	  have	  been	  investigated	  as	  to	  their	  impact	  
on	   prognosis;	   such	   as	   histopathological	   variants	   of	   adenocarcinoma,	   and	   tumour	  
growth	  characteristics.	  For	  example,	  perineural,	  lymphatic	  and	  vascular	  invasion	  have	  
all	  been	  widely	  investigated	  regarding	  their	  prognostic	  value	  in	  rectal	  cancer.	  Patients	  
with	  tumours	  without	  perineural	  invasion	  (PNI)	  have	  approximately	  four	  times	  the	  rate	  
of	  survival	  at	  5	  years	  compared	  to	  patients	  with	  PNI	  (14).	  The	  presence	  of	  PNI	  is	  also	  
associated	   with	   poorly	   differentiated	   tumours,	   lymphatic	   and	   blood	   vessel	   invasion	  
(14).	  	  
	  
Radiological	  features,	  notably	  on	  MRI,	  are	  able	  to	  predict	  prognosis	  in	  terms	  of	  risk	  of	  
local	  and	  distant	  recurrence	  (15).	  MRI	  is	  used	  to	  evaluate	  the	  following	  to	  identify	  high	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risk	   patients	   who	   will	   likely	   require	   neoadjuvant	   therapy;	   circumferential	   resection	  
margin,	  the	  depth	  of	  tumour	  spread	  beyond	  the	  muscularis	  propria,	  extramural	  vascular	  
spread,	   and	   lymph	   node	   status	   (15).	   For	   example,	   extramural	   vascular	   invasion	   is	  
associated	   with	  more	   locally	   advanced	   tumours	   and	   with	   the	   development	   of	   liver	  
metastasis	   (15).	   	  The	  rate	  of	  relapse	  free	  survival	  at	  3	  years	   in	  patients	  with	  positive	  
findings	  of	  extramural	   vascular	   invasion	   is	   less	   than	  half	   that	  of	   those	  with	  negative	  
findings	  (15).	  	  
	  
The	  management	  of	  rectal	  cancer	  is	  guided	  by	  both	  patient	  factors	  and	  tumour	  factors.	  
First,	  it	  is	  recommended	  that	  all	  patients	  with	  rectal	  cancer	  are	  discussed	  in	  a	  colorectal	  
multidisciplinary	  meeting	  (MDM)(9).	  Local	  excision	  of	  a	  T1	  rectal	  cancer	  may	  be	  used	  in	  
selected	   patients	   if	   the	   tumour	   is	   mobile	   and	   less	   than	   3cm,	   and	   not	   poorly	  
differentiated	   on	   biopsy	   (9).	   The	   standard	   management	   of	   locally	   advanced	   rectal	  
cancer	  (Stage	  II	  and	  III	  disease)	  is	  neoadjuvant	  radiation	  or	  chemoradiation	  followed	  by	  
total	  mesorectal	  excision	  (TME)	  surgery.	  This	  current	  multimodal	  approach	  has	  led	  to	  
significant	  improvement	  in	  patient	  outcomes	  over	  the	  recent	  years.	  For	  example	  when	  
TME	   is	   performed	  with	   an	   R0	   resection	   (microscopically	  margin	   negative	   resection),	  
short	   course	   radiotherapy	   (SCR)	   of	   the	   pelvis	   (5	   Gy/day	   for	   5	   days)	   has	   been	  
demonstrated	   to	   further	   reduce	   the	   2-­‐year	   risk	   of	   local	   failure	   after	   surgery	   in	  
comparison	  with	  TME	  alone	  (2.4%	  vs	  8.2%)	  (3).	  	  
	  
1.3.1	  Surgery	  	  
The	  TME	  concept	  was	  a	   revolutionary	  change	   in	   the	   surgical	  management	   for	   rectal	  
cancer	  in	  that	  it	  greatly	  improved	  local	  recurrence	  rates.	  A	  complete	  TME	  is	  described	  
as	   “complete	   removal	   of	   the	   lymph	   node	   bearing	  mesorectum	   along	  with	   its	   intact	  
enveloping	   fascia”(16).	   Current	  mainstay	   surgical	   options	   for	   locally	   advanced	   rectal	  
cancer	   include;	   laparoscopically	   assisted	   or	   open	   high/low	   anterior	   resection	   (AR),	  
abdomino-­‐perineal	   resection	   (APR),	   and	  Hartmann’s	   procedure.	   These	   all	   utilise	   the	  
TME	   technique	   and	   are	   considered	   to	   be	   major	   abdominal	   operations.	   Minimally	  
invasive	  options	  are	  sometimes	  used	  for	  early	  T1	  disease	  and	  include	  transanal	  excisions	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such	   as	   Transanal	   Minimally	   Invasive	   Surgery	   (TAMIS)	   and	   Transanal	   Endoscopic	  
Microsurgery	  (TEMS),	  but	  these	  do	  not	  utilize	  the	  TME	  dissection	  plane.	  	  
	  
In	   rectal	   cancer	   the	   plane	   of	   dissection	   is	   an	   important	   prognostic	   factor	   for	   local	  
recurrence.	  The	  hazard	  ratio	  (HR)	  for	  the	  risk	  of	  local	  recurrence	  is	  decreased	  when	  the	  
plane	  of	  dissection	  removes	  the	  mesorectum	  (HR	  =	  0.32	  (95%	  CI	  0.16-­‐0.64))	  compared	  
with	  the	  intramesorectum	  (HR	  =	  0.48	  (95%	  CI	  0.25-­‐0.93)),	  as	  is	  risk	  of	  local	  recurrence	  
at	  3	  years	  4%	  (3-­‐6%)	  for	  mesorectal	  and	  13%	  (8-­‐21%)	  for	  muscularis	  propria	  dissection	  
(17).	  	  
	  
1.3.2	  Neoadjuvant	  therapy	  
The	  New	  Zealand	  National	  Guidelines	  for	  the	  Management	  of	  Early	  Rectal	  cancer	  state	  
that	   patients	  with	   rectal	   cancer	  who	   are	   at	   risk	   of	   local	   recurrence	   should	   undergo	  
either	  preoperative	  SCR	  or	  preoperative	  LCCR	  (9).	  There	  is	  no	  current	  guideline	  in	  New	  
Zealand	  regarding	  time	  delay	  after	  therapy	  to	  surgery	  and	  there	  is	  some	  variation	  across	  
the	  country	  as	  to	  how	  this	  is	  carried	  out.	  At	  Wellington	  Hospital,	  neoadjuvant	  therapy	  
consists	  of	  either	   long	  course	   radiation	   (50.4	  Gy	   in	  25	   fractions)	   combined	  with	  oral	  
chemotherapy	   generally	   over	   6	   weeks,	   or	   short	   course	   radiation	   of	   25	   Gy	   over	   5	  
fractions,	  typically	  over	  one	  week.	  Surgery	  occurs	  after	  the	  neoadjuvant	  therapy,	  and	  
at	  Wellington	  Hospital	  this	  is	  typically	  6	  weeks	  after	  long	  course	  therapy	  and	  3-­‐5	  days	  
after	  short	  course	  therapy.	  	  
	  
The	  chemotherapy	  agent	  used	  most	  commonly	  is	  Capecitabine,	  a	  5-­‐Fluorouracil	  (5-­‐FU)	  
pro-­‐drug	   (18).	   This	   agent	   has	   nearly	   100%	   bioavailability	   in	   the	   oral	   form.	   It	   is	  
metabolized	  to	  5-­‐FU	  via	  three	  metabolic	  steps	  and	  disrupts	  DNA	  and	  RNA	  synthesis	  and	  
repair,	   leading	   to	   cell	   death	   (18).	   It	   is	   taken	   as	   adjuvant	   therapy	   for	   advanced	   or	  
metastatic	  colon	  cancer	  –	  either	  as	  a	  monotherapy	  or	  with	  combination	  drugs,	  and	  also	  
in	  rectal	  cancer	  with	  concurrent	  radiotherapy	  with	  a	  recommended	  dose	  of	  850	  mg/m2	  
twice	   daily.	   Known	   side	   effects	   specific	   to	   Capecitabine	   are	   diarrhoea,	   leukopenia,	  
stomatitis,	  hand	  and	  foot	  syndrome,	  vomiting	  and	  neuropathy	  (18).	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The	   purpose	   of	   neoadjuvant	   therapy	   is	   to	   decrease	   local	   recurrence,	   increase	   the	  
likelihood	   of	   sphincter	   preservation	   and	   to	   improve	   tumour	   resectability	   (3).	   An	  
important	   concern	   regarding	   neoadjuvant	   therapy	   is	   the	   exposure	   of	   patients	   to	  
unnecessary	   toxins	   and	   their	   effects.	   	   Side	   effects	   of	   	   neoadjuvant	   chemoradiation	  
include	   proctitis,	   sexual	   and	   urinary	   dysfunction,	   fatigue,	   nausea	   and	   vomiting,	   and	  
diarrhoea	  (19).	  In	  addition	  to	  this,	  the	  proportion	  of	  patients	  who	  undergo	  neoadjuvant	  
therapy	   that	   will	   not	   have	   a	   favorable	   response	   will	   suffer	   unnecessary	   delays	   to	  
surgery.	   In	  New	  Zealand	  patients	  may	  need	  to	  relocate	  from	  rural	  centers	  to	  tertiary	  
hospital	  centers	  for	  the	  duration	  of	  their	  therapy,	  which	  can	  lead	  to	  additional	  social	  
isolation	  and	  stress	  to	  patients	  and	  their	  families.	  
	  
However,	  patient	  tumour	  response	  to	  neoadjuvant	  therapy	  is	  varied,	  and	  a	  complete	  
pathological	  response	  (pCR)	  will	  occur	  in	  15%-­‐27%	  of	  patients	  undergoing	  preoperative	  
treatment	  followed	  by	  TME	  surgery	  (4).	  Patients	  with	  pCR	  after	  chemoradiation	  have	  
better	   long-­‐term	   outcomes,	   and	   it	   is	   thought	   that	   pCR	   might	   be	   indicative	   of	   a	  
prognostically	   favourable	   biological	   tumour	   profile	   (20).	   There	   is	   therefore	   great	  
interest	   in	   finding	  biomarkers	   that	   could	   indicate	   the	   likelihood	  of	   response	  prior	   to	  
administering	  this	  treatment.	  	  
	  
1.4	  Assessing	  response	  to	  neoadjuvant	  therapy	  
Response	  to	  neoadjuvant	  therapy	  is	  an	  important	  prognostic	  indicator	  for	  patients	  and	  
is	  measured	  after	  surgery	  using	  both	  Tumour	  Regression	  Grade	  (TRG),	  and	  pathological	  
stage	  by	  TNM	  stage.	  	  
	  
1.4.1	  Tumour	  Regression	  Grading	  
Tumour	  Regression	  Grade	   (TRG)	   is	  now	  part	  of	   the	   standard	   synoptic	   reporting	  of	  a	  
pathological	   specimen,	   particularly	   for	   patients	  who	   have	   undergone	   LCCR.	   Tumour	  
regression	   grading	   systems	   are	   predictive	   of	   both	   disease	   free	   survival	   (21),	   local	  
recurrence,	  and	  local	  node	  involvement	  (12).	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There	  are	  a	  number	  of	  grades	  utilised	  for	  tumour	  regression	  reporting	  including	  Dworak	  
(22),	  Mandard,	  Dworak/Rodel,	  American	  Joint	  Commission	  on	  Cancer	  (AJCC),	  (23),	  and	  
the	  Ryan	  classification	  (24,	  25).	  No	  absolute	  standard	  method	  is	  used	  worldwide	  but	  all	  
of	  these	  systems	  are	  based	  on	  the	  on	  the	  degree	  of	  fibrosis	  and	  percentage	  of	  viable	  
cancer	   cells	   as	   assessed	   by	   a	   trained	   pathologist.	   Grades	   vary	   from	   absence	   of	  
regression	  for	  non-­‐responders,	  to	  decreasing	  amounts	  of	  tumour	  cells	  within	  fibrotic	  
tissue,	   to	   no	   tumour	   cells,	   termed	   complete	   regression	   (pCR)	   (24).	   For	   research	  
purposes,	  patients	   are	   typically	   grouped	   into	   complete	   responders,	   intermediate,	  or	  
poor	  responders.	  	  
	  
The	  time	  delay	  from	  the	  end	  of	  neoadjuvant	  therapy	  to	  surgery	  is	  now	  known	  to	  impact	  
on	   tumour	   regression	   (26).	   Prolonging	   the	   time	   to	   surgery	   after	   SCR	   from	   the	  
conventional	  5	  days	  to	  4	  weeks	  markedly	  increases	  the	  rate	  of	  complete	  pathological	  
response	   and	   tumour	   downstaging	   and	   also	   lowers	   the	   rate	   of	   post	   operative	  
complications.	   However,	   there	   is	   no	   difference	   in	   overall	   survival,	   sphincter	  
preservation,	  or	  R0	  resection	  rates	  (26).	  	  
	  
1.4.2	  Pathological	  staging	  
The	   AJCC	   TNM	   staging	   system	   is	   universally	   accepted	   for	   pathological	   specimen	  
reporting	  for	  rectal	  cancer	  and	  allows	  for	  national	  and	  international	  comparisons.	  The	  
pathological	   stage	   allows	   for	   decisions	   to	   be	  made	   about	  whether	   the	   patient	  may	  
benefit	  from	  adjuvant	  chemotherapy	  and	  to	  give	  some	  indication	  of	  prognosis.	  These	  
decisions	  are	  made	  on	  a	  case	  by	  case	  basis	  by	   the	  Colorectal	  MDM.	  Currently,	  TNM	  
staging	  is	  considered	  the	  best	  prognostic	  classification	  tool	  to	  help	  guide	  therapeutic	  
decisions	  for	  CRC	  (27).	  Whilst	  the	  initial	  TNM	  stage	  is	  made	  from	  imaging	  completed	  
prior	  to	  surgery,	  following	  surgery,	  the	  stage	  is	  re-­‐reported	  by	  pathology.	  Differences	  in	  
preoperative	  stage	  and	  pathological	  stage	  can	  be	  used	  as	  evidence	  of	  downstaging	  of	  
the	  tumour	   in	  response	  to	  neoadjuvant	  treatment,	  however	  TRG	  is	  considered	  more	  
accurate	  as	  it	  could	  be	  that	  the	  differences	  were	  due	  to	  the	  comparison	  of	  two	  different	  
modalities.	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1.5	  Predictive	  biomarkers	  for	  response	  to	  neoadjuvant	  therapy	  
Given	  that	  currently	  we	  cannot	  predict	  with	  confidence	  which	  patients	  will	  benefit	  from	  
neoadjuvant	  therapy,	  the	  individual	  patient	  requirement	  for	  this	  treatment	  is	  uncertain.	  
The	   previously	   mentioned	   factors	   for	   predicting	   local	   recurrence	   risk,	   and	   overall	  
survival	   are	   all	   based	   on	   post-­‐operative	   specimen	   analysis.	   There	   is	   considerable	  
interest	  and	  investigation	  into	  robust	  biomarkers	  that	  can	  be	  used	  prior	  to	  surgery	  to	  
aid	   in	   risk	   stratification	   and	   to	   personalise	   treatment.	   Patients	   that	   respond	  well	   to	  
neoadjuvant	  therapy	  may	  not	  need	  surgery	  or	  adjuvant	  treatment,	  and	  patients	  that	  
will	  not	  respond	  may	  proceed	  straight	  to	  surgery	  and	  avoid	  the	  need	  for	  any	  ineffective	  
toxic	  therapy.	  
	  
In	   recent	   years	   there	   have	   been	   considerable	   advances	   in	   developing	   the	   use	   of	  
molecular	  biomarkers	  for	  the	  prognosis	  and	  prediction	  of	  treatment	  response	  in	  CRC.	  
In	  terms	  of	  prognosis,	  examples	  of	  clinically	  utilised	  tissue	  biomarkers	  are	  Microsatellite	  
Instability	   (MSI)	   and	   the	   KRAS	   gene.	  MSI	   is	   a	   phenotype	   of	   a	   DNA	  mismatch	   repair	  
(MMR)	   system	   defect	   and	   is	   observed	   in	   10-­‐15%	   of	   spontaneous	   CRC	   cases	   (28).	  
Patients	  can	  be	  classified	  into	  MSI-­‐H	  (high),	  MSI-­‐L	  (low)	  or	  microsatellite	  stable	  tumours.	  
Patients	  with	  MSI-­‐H	  or	  MMR	  deficient	  tumours	  have	  a	  favourable	  prognosis,	  and	  do	  not	  
derive	  any	  benefit	  from	  adjuvant	  5-­‐FU	  based	  chemotherapy	  (29).	  	  KRAS	  is	  a	  commonly	  
mutated	  oncogene	  in	  CRC.	  In	  patients	  with	  advanced	  CRC,	  mutations	  of	  KRAS	  predict	  a	  
failure	   to	   respond	   to	   Cetuximab;	   a	   monoclonal	   antibody	   against	   epidermal	   growth	  
factor	  receptor,	  compared	  to	  supportive	  care	  alone.	  Patients	  with	  a	  wild	  type	  KRAS	  gene	  
have	   a	   doubling	   of	   the	   median	   overall	   survival	   (median	   9.5	   months	   vs	   4.8	   months	  
p<0.001)	   and	   progression	   free	   survival	   (3.7	   vs	   1.9	  months,	   p<0.001)(30).	   These	   are	  
examples	   of	   how	   molecular	   biomarkers	   can	   be	   used	   for	   predicting	   response	   to	  
therapies	  in	  CRC	  patients.	  	  
	  
Extensive	   research	   has	   been	   conducted	   on	   tissue	   based	   biomarkers	   to	   determine	   if	  
there	   is	   correlation	   with	   pCR.	   Hur	   et	   al.	   used	   tissue	   microarrays	   and	  
immunohistochemistry	  to	  look	  at	  12	  biomarkers	  including	  Ki-­‐67,	  p53,	  p21,	  and	  Bax	  (31).	  
Of	  these	  12	  markers,	  the	  expression	  levels	  of	  four	  (p53,	  VEFG,	  p21,	  and	  Ki67)	  differed	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significantly	  between	  patients	  who	  achieved	  pCR	  and	  those	  that	  did	  not.	  When	  these	  
four	  markers	  were	  combined	  into	  a	  scoring	  system,	  there	  was	  good	  sensitivity	  (96.3%)	  
but	  not	  specificity	  (46.3%)	  for	  pCR	  (31).	  It	  is	  noted	  however,	  that	  this	  was	  a	  retrospective	  
study	   looking	  at	  81	   samples.	   The	   results	   from	   this	   study	  were	  potentially	   subject	   to	  
selection	  bias	  with	  only	  those	  with	  enough	  tissue	  being	  able	  to	  be	  examined	  (31).	  The	  
appropriateness	   of	   this	   scoring	   system	   would	   still	   need	   to	   be	   validated	   with	   an	  
independent	  cohort.	  	  	  
	  
Despite	  this	  progress,	  tissue	  biomarkers	  have	  some	  significant	  limitations	  and	  have	  not	  
been	  implemented	  clinically.	  First,	  harvesting	  tumour	  biopsies	  can	  expose	  patients	  to	  
some	  risk	  of	  perforation	  and	  bleeding.	  Statistics	  from	  the	  New	  Zealand	  bowel	  cancer	  
screening	   program	   show	   a	   rate	   of	   bleeding	   in	   patients	   with	   tissue	   removed	   during	  
colonoscopy	  to	  be	  7.9/1000	  colonoscopies,	  and	  perforation	  rate	  to	  be	  1.2/1000	  (32).	  It	  
is	   important	   to	   note	   however,	   that	   these	   rates	   refer	   to	   full	   colonoscopies	   including	  
polypectomies,	  not	   just	  biopsies.	  Also,	  endoscopic	  biopsies	   can	  be	  unreliable	  due	   to	  
sampling	  error.	  CRC	  tumours	  are	  heterogenous	  in	  nature	  (33)	  and	  a	  biopsy	  may	  not	  be	  
representative	  as	  to	  what	  is	  happening	  in	  other	  parts	  of	  the	  tumour.	  In	  addition	  to	  this,	  
in	  most	  cases	  endoscopy	  is	  performed	  once	  per	  patient	  usually	  prior	  to	  surgery	  due	  to	  
its	  relatively	  invasive	  nature.	  	  
	  
1.5.1	  Liquid	  biopsies	  	  
Liquid	  biopsies,	  or	  blood-­‐based	  biomarkers	  present	  as	  an	  attractive	  alternative	  to	  tissue	  
biopsy	  as	  they	  are	  easily	  accessible	  and	  safe	  to	  acquire.	  If	  taken	  prior	  to	  neoadjuvant	  
therapy	  starting,	  they	  would	  have	  a	  higher	  clinical	  utility	  to	  help	  with	  decision	  making	  
regarding	  treatment,	  all	  prior	  to	  obtaining	  a	  surgical	  specimen.	  It	  would	  also	  be	  possible	  
to	  take	  multiple	  or	  consecutive	  samples	  during	  treatment	  to	  monitor	  response	  at	  no	  
further	  risk	  to	  the	  patient.	  	  
	  
One	  example	  of	   a	   clinically	   used	  blood	  biomarker	   in	   CRC	   is	   CEA,	  which	   is	   used	   as	   a	  
marker	  for	  disease	  recurrence.	  CEA	  is	  more	  sensitive	  at	  detecting	  CRC	  recurrence	  than	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chest	   X-­‐ray,	   ultrasound	   of	   the	   liver,	   liver	   function	   studies,	   or	   colonoscopy	   and	   is	  
comparable	  to	  CT	  scan	  (34).	  There	  have	  been	  multiple	  studies	  exploring	  the	  predictive	  
role	   of	   CEA	   in	   response	   to	   neoadjuvant	   therapy.	   The	   majority	   of	   studies	   have	  
demonstrated	  that	  a	  lower	  CEA	  is	  associated	  with	  higher	  rates	  of	  pCR	  however	  these	  
studies	  are	  retrospective	  in	  their	  design	  and	  all	  have	  different	  CEA	  cut	  off	  values	  (35).	  
CEA	  is	  not	  currently	  used	  clinically	  for	  predicting	  response	  to	  neoadjuvant	  therapy	  as	  
data	  is	  still	  requires	  validation	  in	  larger	  prospective	  trials	  (35).	  	  
	  	  
Part	  of	  the	  routine	  preoperative	  work	  up	  for	  CRC	  patients	  includes	  measuring	  C	  Reactive	  
Protein	  (CRP),	  white	  blood	  cells,	  neutrophils,	  lymphocytes.	  It	  has	  been	  shown	  that	  CRP	  
is	  a	  sensitive	  but	  non-­‐specific	  marker	  of	   inflammation.	  Despite	  known	   links	  between	  
inflammation	  and	  cancer,	  there	  is	  a	  very	  weak	  association	  between	  elevated	  CRP	  and	  
increased	  risk	  of	  CRC	  as	  demonstrated	  in	  a	  meta-­‐analysis	  by	  Tsilidis	  et	  al.	  They	  	  found	  
that	  there	  was	  an	  increased	  relative	  risk	  for	  colon	  cancer	  with	  each	  increase	  in	  unit	  of	  
CRP,	  with	  a	  RR	  1.13,	  (95%	  CI;	  1.00-­‐1.27)	  but	  not	  for	  rectal	  cancer,	  (RR	  1.06	  (95%	  CI	  0.86-­‐
1.30))	   (36).	  The	  Neutrophil	   to	  Lymphocyte	  Ratio	  (NLR)	  has	  also	  been	  explored	  for	   its	  
predictive	  use.	  A	  meta-­‐analysis	  by	  Li	  et	  al.	   looking	  at	  solid	  tumours	  (including	  breast,	  
bladder,	   rectal	   and	   gastric)	   demonstrated	   a	   lower	   NRL	   was	   associated	   with	   better	  
overall	   survival,	   disease	   free	   survival	   and	   recurrence	   free	   survival	   (37).	   Specifically,	  
when	  looking	  at	  neoadjuvant	  therapy	  in	  rectal	  cancer	  patients,	  patients	  with	  lower	  NLR	  
had	  an	  increased	  rate	  of	  pCR	  (OR	  2.01,	  95%	  CI	  =	  1.14-­‐3.55).	  	  
	  
Despite	  this	  work,	  there	  are	  no	  blood	  biomarkers	  used	  in	  a	  clinical	  setting	  to	  predict	  
response	   to	   neoadjuvant	   therapy	   in	   rectal	   cancer.	   There	   are	   several	   new	   classes	   of	  
biomarkers	  including	  microRNAs	  (miRNA)	  which	  are	  particularly	  attractive	  because	  they	  
are	  stable	  in	  blood.	  Emerging	  research	  suggests	  that	  miRNA	  may	  be	  potentially	  useful	  
in	  the	  early	  detection,	  prognosis	  and	  as	  therapeutic	  targets	  for	  CRC	  (38).	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DNA	  mutation/DNA	  methylation	   KRAS	   Unlikely	  to	  be	  able	  to	  
predict	  response	  to	  
treatment	  (35).	  	  
TP53	   Mutation	  possibly	  
associated	  with	  resistance	  
to	  LCCR	  (39),	  but	  majority	  
of	  studies	  reveal	  no	  
correlation	  between	  p53	  
and	  treatment	  outcome	  
(40)	  
Gene	  expression	  	   NPTX2	   Decreased	  levels	  
associated	  with	  increased	  
response	  to	  therapy	  (41).	  
Proteins	   NF-­‐KB	   No	  significant	  association	  
(42).	  	  
Tumour	  microenvironment	   PD-­‐L1	   Inconsistent	  findings	  (42).	  
miRNA	   miR-­‐135b	   Expression	  levels	  
significantly	  correlated	  
with	  pCR	  .	  
miR-­‐21	   Increased	  in	  pCR	  (43).	  
	   miR-­‐145	   Significant	  correlation	  -­‐	  
patients	  with	  a	  low	  
intratumoral	  post-­‐
therapeutic	  expression	  had	  
a	  worse	  response	  to	  
neoadjuvant	  therapy	  AUC	  
of	  ROC	  curve	  0.696	  (p	  =	  
0.031)	  (44).	  








Protein/metabolites	   CEA	   Conflicting	  results,	  seems	  
to	  be	  dependent	  on	  cut	  off	  
level	  of	  CEA	  used.	  Better	  
for	  predicting	  prognosis	  
but	  not	  TRG	  (42).	  	  
Fibrinogen	   Elevated	  levels	  associated	  
with	  pCR	  (45).	  Poor	  
sensitivity.	  	  
miRNA	   miR-­‐125b	   Significantly	  elevated	  in	  
non-­‐responders	  (46).	  	  
miR-­‐143	   Serum	  miR-­‐143	  significant	  
association	  with	  pCR	  (47).	  
Host	  immune	  response	   IL-­‐6	  and	  
TNF-­‐α	  
Levels	  after	  therapy	  higher	  
in	  non-­‐responders	  (48).	  
NLR	   Higher	  NLR	  associated	  with	  
poor	  response	  to	  therapy	  
(37).	  
	  
Abbreviations:	  KRAS,	  Kirsten	  rat	  sarcoma	  viral	  oncogene	  homolog;	  NPTX2,	  neuronal	  pentraxin	  II;	  EGFR,	  
epidermal	  growth	  factor	  receptor;	  PD-­‐L1,	  programmed	  cell	  death	  ligand	  1;	  MDSCs,	  Myeloid-­‐Derived	  
Suppressor	  Cells;	  CEA,	  carcinoembryonic	  antigen;	  IL,	  interleukin;	  NLR,	  Neutrophil-­‐to-­‐lymphocyte	  ratio;	  
TNF	  Tumour	  Necrosis	  Factor;	  NFKB,	  Nuclear	  factor	  kappa-­‐light-­‐chain-­‐enhancer	  of	  activated	  B	  cells.	  
	  
1.6	  MicroRNA	  as	  biomarkers	  
MicroRNA	  (miRNA)	  are	  short	  non-­‐coding	  RNA’s	  that	  are	  expressed	  in	  all	  cell	  types.	  	  They	  
work	   by	   regulating	   translation	   and	   stability	   of	   specific	   target	   messenger	   RNA	   (38).	  
Changes	   in	  miRNA	  expression	  are	   frequently	  associated	  with	  abnormal	  cell	   function,	  
notably	   certain	   cancers.	   They	   are	   thought	   to	   target	   oncogenes,	   tumor	   suppressor	  
genes,	  and	  mRNA	   in	   the	  cell.	   Therefore,	  miRNA	  have	  been	  classified	  as	  being	  either	  
oncogenic	  or	  having	   tumour	  suppressor	   function	   in	   relation	   to	  whether	   their	  overall	  
effect	   is	   pro	   or	   anti	   tumour.	   Their	   expression	   in	   cancer	   has	   now	   been	   extensively	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reported	  and	  their	  clinical	  utility	  as	  both	  biomarkers	  and	  therapeutic	  targets	  for	  disease	  
is	  a	  rapidly	  growing	  area	  of	  research	  (38).	  Importantly,	  miRNA	  are	  stable	  in	  biofluids	  due	  
to	   a	   number	   of	   reasons	   (49).	   	   First,	   they	   are	   transported	   in	   small	   double	   lipid	   layer	  
vesicles	  called	  exosomes,	  a	  form	  of	  extracellular	  vesicle.	  Secondly,	  a	  portion	  of	  miRNA	  
that	  are	  not	  transported	  in	  these	  vesicles	  are	  co-­‐transported	  with	  protein	  Argonaute	  2,	  
or	  they	  can	  be	  carried	  by	  lipoproteins	  (50).	  miRNA	  are	  stable	  for	  long	  periods	  of	  time	  
when	  stored	  properly	  and	  can	  endure	  repeated	  freeze-­‐thaw	  cycles	  (51).	  	  
	  
miRNA	  also	  have	  a	  functional	  role	  in	  cancer,	  and	  immunology	  is	  an	  example	  of	  this	  as	  
miRNA	   are	   key	   modulators	   of	   tumour	   immune	   response.	   miRNA	   serve	   as	   crucial	  
regulators,	   specifically	   by	   controlling	   the	   development	   and	   functions	   of	   tumour	  
associated	  immune	  cells	  and	  the	  tumour	  microenvironment	  (52)	  .	  	  
	  
1.7	  MicroRNA	  in	  colorectal	  cancer	  
There	  is	  currently	  considerable	  interest	  into	  how	  the	  expression	  of	  miRNA	  can	  be	  used	  
for	  CRC	  diagnostic,	  prognostic	  and	  predictive	   tests	   (53).	  Multiple	  miRNAs	  have	  been	  
found	  to	  be	  over	  and	  under	  expressed	  specifically	  in	  CRC	  patients	  (54).	  miRNA	  were	  first	  
shown	  to	  be	  dysregulated	   in	  CRC	  tumour	  tissue	  when	  compared	  to	  normal	  adjacent	  
mucosa	  (55).	  Since	  then,	  they	  have	  also	  be	  found	  to	  be	  dysregulated	  in	  the	  systemic	  
circulation	  of	   CRC	  patients	  when	   compared	   to	   normal	   controls	   (55).	  MiRNA	   relative	  
expression	   levels	  have	  been	  associated	  with	  CRC	  stage,	  prognosis,	   tumour	  bulk,	  and	  
response	  to	  treatment	  (38,	  56).	  	  
	  
We	  have	  focused	  on	  four	  miRNAs	  that	  have	  previously	  been	  associated	  with	  CRC	  but	  
have	  not	  been	  investigated	  for	  their	  relationship	  between	  plasma	  levels	  and	  response	  
to	  neoadjuvant	  therapy.	  	  
	  
1.7.1	  miR-­‐21	  
miR-­‐21	  is	  an	  oncogenic	  miRNA	  with	  elevated	  expression	  levels	  in	  CRC	  tissue	  (38),	  (55),	  
(57).	  Multiple	  studies	  have	  evaluated	  the	  diagnostic	  ability	  of	  circulating	  miR-­‐21	  in	  CRC	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patients.	  The	  majority	  have	  shown	  significant	  associations	  with	  elevated	  miR-­‐21	  and	  
CRC.	   One	   study	   has	   shown	   the	   ability	   of	  miR-­‐21	   in	   serum	   to	   differentiate	   between	  
adenomatous	  polyps	  and	  healthy	  control	  patients	   (56).	  A	   few	  studies	  have	  found	  no	  
difference	  in	  miR-­‐21	  relative	  expression	  in	  plasma	  between	  CRC	  and	  control	  patients	  
(58).	  	  
	  
As	  well	  as	  overexpression	  in	  CRC,	  miR-­‐21	  has	  been	  investigated	  as	  a	  marker	  for	  pCR.	  
Lopes-­‐Ramos	   et	   al.	   (57)	   found	   that	   in	   tumour	   biopsies	   taken	   prior	   to	   neoadjuvant	  
therapy,	  there	  was	  markedly	  increased	  expression	  of	  miR-­‐21-­‐5p,	  miR-­‐1290-­‐3p	  and	  miR-­‐
1246	  in	  patients	  with	  complete	  response,	  and	  increased	  expression	  of	  miR-­‐205-­‐5p	  in	  
patients	  with	   incomplete	   response.	   The	   authors	   then	   evaluated	  which	  miRNA	   could	  
predict	  response	  to	  chemoradiation	  with	  highest	  accuracy	  and	  found	  that	  miR-­‐21	  had	  
an	  area	  under	  the	  curve	  (AUC)	  0.94	  on	  receiver	  operating	  curve	  (ROC)	  with	  sensitivity	  
of	  100%	  and	  specificity	  of	  85%	  (57).	   	  They	  did	  not	  find	  on	  validation	  studies	  that	  the	  
other	  miRNA	  were	  differentially	  expressed.	  Of	  note	  the	  “complete	  responders”	  group	  
was	   comprised	   of	   both	   those	  with	   pathological	   specimen	   evidence	   of	   pCR	   and	   also	  
those	  with	  clinical	  evidence	  of	   complete	   response	   (assessed	  clinically	  endoscopically	  
and	  radiologically).	  Those	  that	  were	  considered	  to	  be	  clinically	  pCR	  were	  enrolled	  in	  a	  
Watch	   and	   Wait	   program.	   Therefore,	   not	   all	   of	   the	   patients	   have	   pathological	  
specimens	   to	   validate	  pCR	   response.	   The	  authors	  had	  a	   group	  of	  patients	  who	   they	  
initially	   termed	   “complete	   responders”	   but	   then	   went	   on	   to	   develop	   early	   local	  
recurrence.	   Interestingly,	  these	  patients	  had	  significantly	   lower	  miR-­‐21	  expression	  to	  
the	  pCR	  group	  and	  expression	  levels	  were	  lower,	  similar	  to	  the	  incomplete	  responders	  
group.	  This	  could	  demonstrate	  that	  miR-­‐21	  could	  be	  useful	  to	  select	  patients	  who	  are	  
suitable	  for	  Watch	  and	  Wait	  management	  strategies.	  Regarding	  mechanisms	  for	  how	  
miR-­‐21	  may	  effect	  neoadjuvant	  response,	  the	  authors	  also	  found	  that	  in	  vitro	  studies	  
using	  colorectal	  tumour	  cell	   lines	  (HCT116	  and	  SW480),	  SATB1,	  a	  miR-­‐21	  target	  gene	  
which	   is	   associated	   with	   multidrug	   resistance	   may	   be	   directly	   involved	   with	   poor	  
response	  to	  neoadjuvant	  therapy.	  
	  
In	   a	   retrospective	   study	   by	   Carames	   et	   al.	   (43),	   the	   authors	   found	   miR-­‐21	  
overexpression	  in	  rectal	  tumour	  tissue	  samples	  taken	  post	  neoadjuvant	  treatment	  and	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post-­‐surgery	   in	   77%	   of	   patients.	   The	   authors	   state	   that	   miR-­‐21	   overexpression	  
correlated	  with	  postoperative	  tumour	  grade	  and	  pathological	  response.	  Patients	  were	  
considered	   to	   have	   “low”	   expression	   of	  miR-­‐21	  when	   expression	   levels	   (-­‐ΔCT)	  were	  
below	  2.8.	  Of	  the	  10	  patients	  that	  had	  pCR,	  6	  had	  “low”	  and	  four	  had	  “high”	  miR-­‐21.	  For	  
those	  with	   incomplete	   response,	   8	   had	   “low”	  miR-­‐21	   and	   52	   had	   “high”	  miR-­‐21	   (p	  
=0.0130).	  This	   is	  a	  notably	   small	  number	  of	  patients	  with	  pCR,	  more	  of	  which	  had	  a	  
“low”	  miR-­‐21.	   The	  main	   issue	  with	   this	   retrospective	   strategy	   is	  with	   using	   samples	  
taken	   after	   neoadjuvant	   therapy	   and	   surgery.	   We	   cannot	   extrapolate	   that	   these	  
changes	  in	  expression	  would	  be	  the	  same	  in	  patients	  prior	  to	  treatment	  and	  therefore	  
useful	  clinically	  to	  answer	  predictive	  questioning.	  	  
	  
Currently	  it	   is	  not	  clear	  as	  to	  how	  useful	  circulating	  miR-­‐21	  is	   in	  a	  predictive	  context.	  
While	  the	  abovementioned	  studies	  have	  looked	  at	  tissue	  miR-­‐21,	  plasma	  miR-­‐21	  has	  
not	  been	  analysed	  for	  their	  role	  in	  predicting	  response	  to	  neoadjuvant	  therapy.	  
	  
1.7.2	  miR-­‐29a	  
MiR-­‐29a	   has	   been	   reported	   to	   be	   dysregulated	   in	   a	   number	   of	   cancers	   including	  
prostate	  cancer,	  myeloid	  leukemia,	  lung	  cancer,	  and	  gliobalstoma,	  cholangiocarcinoma	  
and	  CRC	  (59).	  Specifically	  miR-­‐29a	  has	  been	  shown	  to	  be	  upregulated	  2.3	  fold	  in	  rectal	  
cancer	  tissue	  (55).	  MiR-­‐29a	  has	  been	  associated	  with	  tumour	  aggressiveness	  and	  with	  
later	  stage	  cancer.	  Tang	  et	  al.	  have	  reported	  that	  an	  increased	  expression	  of	  miR-­‐29a	  
leads	   to	   a	   decreased	   expression	   of	   KLF4	   gene,	   which	   is	   a	   well-­‐established	   tumour	  
suppressor	   gene	   in	  CRC	  and	  has	  been	   implicated	   in	   cell	   proliferation,	  migration	  and	  
invasion	  (60).	  The	  authors	  also	  analysed	  the	  expression	  levels	  in	  85	  cases	  of	  CRC	  tissues	  
(surgical	   specimens)	   using	   RT-­‐qPCR	   and	   found	   a	   high	   expression	   of	   miR-­‐29a	   was	  
significantly	  correlated	  with	  metastatic	  disease	  (p	  =	  0.28).	  Serum	  levels	  of	  miR-­‐29a	  have	  
been	  reported	  to	  be	  significantly	  higher	  in	  stage	  III	  CRC	  patients	  compared	  to	  controls	  
(61).	   We	   have	   selected	   this	   as	   a	   target	   miRNA	   because	   circulating	   levels	   could	  
potentially	  give	  some	  biological	  information	  on	  the	  rectal	  tumour	  that	  would	  be	  useful	  
for	  deciding	  if	  neoadjuvant	  therapy	  is	  necessary.	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1.7.3	  miR-­‐143	  and	  miR-­‐145	  
MiR-­‐143	  and	  miR-­‐145	  have	  both	  been	  reported	  to	  have	  decreased	  expression	  in	  CRC	  
tissue.	  	  miR-­‐143	  expression	  has	  also	  been	  shown	  to	  decrease	  specifically	  in	  colon	  cancer	  
tissue,	  but	  not	  in	  rectal	  cancer	  tissue	  (54,	  55,	  62).	  In	  a	  study	  by	  Li	  et	  al,	  miR-­‐143	  relative	  
expression	  in	  rectal	  tissue	  from	  surgical	  specimens	  (snap	  frozen)	  was	  decreased	  4.82	  
fold	   in	   colon	   cancer,	   but	   did	   not	   change	   significantly	   in	   rectal	   cancer	   (55).	   This	  
potentially	  highlights	  the	  heterogeneity	  in	  the	  biology	  of	  these	  cancers.	  	  	  	  
	  
MiR-­‐143	  and	  miR-­‐145	  are	  reported	  to	  have	  tumour	  suppressive	  functions	  in	  CRC	  (38).	  
Both	  have	  been	  shown	  to	  regulate	  cell	  growth	  and	  proliferation	  in	  in	  vitro	  studies.	  MiR-­‐
143	  has	  been	  shown	  to	  inhibit	  translation	  of	  KRAS	  (63).	  There	  is	  some	  evidence	  that	  p53	  
regulates	  miR-­‐145,	  and	  that	  miR-­‐145	  modulates	  multiple	  oncogenes	  including	  insulin	  
receptor	  substrate-­‐1	  (IRS-­‐1),	  EGFR,	  MUC-­‐1,	  and	  SOX2.	  The	  tumour	  suppressive	  function	  
of	  miR-­‐145	  is	  related	  to	  regulation	  of	  cell	  proliferation	  via	  its	  targeting	  of	  IRS-­‐1	  (64).	  	  	  	  
	  
Arndt	  et	  al	  (62).	  analysed	  the	  expression	  of	  miRNA	  in	  both	  clinical	  CRC	  samples	  (n=45)	  
and	  8	  CRC	   cell	   line	  models,	   of	  which	   they	   found	  37	  miRNAs	   that	  were	  differentially	  
expressed.	  They	  focused	  on	  miR-­‐143	  and	  miR-­‐145	  and	  transduced	  miR-­‐143	  or	  miR-­‐145	  
vectors	  into	  SW620	  CRC	  cells	  and	  analysed	  their	  cell	  proliferation,	  differentiation	  and	  
anchorage-­‐independent	  growth.	  There	  is	  possibly	  some	  function	  of	  miR143	  that	  has	  a	  
tumour	  suppressor	  effect	  in	  metastatic	  CRC	  cells,	  and	  that	  conversely	  miR-­‐145	  has	  some	  
oncogenic	  effect	  in	  metastatic	  CRC	  cells	  with	  increase	  in	  cell	  proliferation	  and	  metabolic	  
activity,	  and	  an	  increase	  in	  anchorage-­‐independent	  growth	  (62).	  	  	  
	  
In	  terms	  of	  predictive	  tests,	  Drebber	  et	  al.	  (44)	  examined	  relative	  expression	  of	  miR-­‐21,	  
miR-­‐143	   and	   miR-­‐145	   in	   tissue	   of	   forty	   patients	   with	   advanced	   rectal	   cancer,	   and	  
assessed	  tumour	  response	  to	  neoadjuvant	  therapy	  with	  TRG.	  The	  authors	  found	  that	  
miR-­‐143	  and	  miR-­‐145	  were	  significantly	  upregulated	  in	  tissue	  after	  LCCR.	  A	  significant	  
correlation	  between	  miR-­‐145	  expression	  and	  tumour	  regression	  was	  also	  seen,	  in	  that	  
patients	  with	  a	  low	  intratumoral	  post-­‐therapeutic	  expression	  had	  a	  worse	  response	  to	  
neoadjuvant	  therapy	  AUC	  of	  ROC	  curve	  0.696	  (p	  =	  0.031).	  Regarding	  circulating	  levels,	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there	   is	  one	  recent	  prospective	  study	   looking	  at	  the	  association	  of	  TRG	  to	  LCCR	  with	  
serum	  miR-­‐143,	  in	  which	  the	  authors	  report	  it	  to	  be	  an	  independent	  predictor	  of	  good	  
response	  in	  locally	  advanced	  rectal	  cancer	  patients,	  which	  is	  very	  encouraging	  (47).	  	  
	  
1.8	  Conclusion	  
Rectal	  cancer	  is	  an	  important	  problem	  in	  New	  Zealand.	  Patients	  with	  locally	  advanced	  
disease	  are	  currently	  managed	  with	  neoadjuvant	  therapy	  and	  surgery.	  Due	  to	  the	  varied	  
patient	  response	  to	  neoadjuvant	  therapy,	  there	  is	  a	  need	  to	  determine	  which	  patients	  
will	  benefit	  prior	  to	  administering	  this	  treatment.	  Currently	  there	  are	  no	  clinically	  used	  
blood	  biomarkers	  to	  predict	  patient	  response.	  There	  is	  a	  growing	  appreciation	  for	  the	  
role	   of	   miRNAs	   in	   CRC	   and	   new	   research	   into	   how	   these	   could	   be	   used	   to	   predict	  
response	   to	   neoadjuvant	   therapy.	   	   Developing	   these	   tests	   would	   allow	   patients	   to	  
receive	  optimal	  therapy	  and	  avoid	  ineffective	  and	  potentially	  harmful	  treatments.	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Hypothesis	  and	  Aims	  	  
We	  hypothesise	  that	  circulating	  plasma	  miR-­‐21,	  miR-­‐29a,	  miR-­‐143	  and	  miR-­‐145	  could	  
act	  as	  biomarkers	  for	  the	  detection	  of	  CRC	  and	  as	  predictors	  of	  response	  to	  
neoadjuvant	  chemoradiation	  therapy.	  	  
	  
Our	  specific	  aims	  are:	  
	  
1.	  To	  determine	  whether	  plasma	  levels	  of	  miR-­‐21,	  miR-­‐143,	  miR-­‐145	  and	  miR-­‐29a	  
have	  altered	  expression	  in	  patients	  with	  stage	  II/III	  rectal	  cancer	  compared	  to	  controls.	  
Target	  miRNA	  levels	  will	  be	  measured	  in	  plasma	  samples	  from	  rectal	  cancer	  patients	  
and	  control	  patients	  using	  RT-­‐qPCR.	  	  
	  
2.	  To	  determine	  whether	  plasma	  levels	  of	  miR-­‐21,	  miR-­‐143,	  miR-­‐145,	  and	  miR29a,	  taken	  
prior	   to	   neoadjuvant	   treatment	   can	   act	   as	   predictive	   markers	   of	   response	   to	  
neoadjuvant	  therapy.	  We	  will	  compare	  baseline	  plasma	  target	  miRNA	  expression	  from	  
stage	  II/III	  rectal	  cancer	  patients	  who	  respond	  to	  SCR	  and	  LCCR	  vs	  non	  responders.	  	  
	  
3.	  To	  investigate	  changes	  in	  plasma	  levels	  of	  these	  miRNA	  in	  response	  to	  neoadjuvant	  
therapy	  as	  markers	  of	  therapeutic	  response.	  We	  will	  compare	  baseline	  plasma	  target	  
miRNA	  expression	  from	  stage	  II/III	  rectal	  cancer	  patients	  who	  respond	  to	  SCR	  and	  LCCR	  
with	  post	  therapy	  expression	  to	  determine	  whether	  circulating	  miRNA	  levels	  change	  as	  
an	  indicator	  of	  response	  to	  therapy.	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Chapter	  2:	  	  
Methods	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2.1	  Patient	  recruitment	  	  
2.1.1	  Colorectal	  Cancer	  Biobank	  
Patients	   with	   CRC	  were	   recruited	   for	   donation	   of	   blood	   and	   tissue	   for	   a	   Colorectal	  
Cancer	   Biobank	   under	   ethical	   approval	   by	   Health	   and	   Disability	   Ethics	   Committee	  
(‘Establishment	   of	   human	   tissue	   bank	   of	   surgical	   cancers	   for	   future	   unspecified	  
research,	   ref:	   15/CEN/143).	   MicroRNA	   measurement	   for	   the	   proposed	   study	   was	  
approved	   by	   the	   Health	   and	   Disability	   Ethics	   Committee	   (‘Molecular	   biomarkers	   in	  
colorectal	  cancer’,	  ref:	  18/CEN/138).	  Consultation	  was	  also	  undertaken	  with	  the	  Ngai	  
Tahu	   Research	   Consultation	   Committee	   for	   this	   project.	   All	   work	  was	   performed	   in	  
accordance	  with	  the	  Declaration	  of	  Helsinki	  and	  all	  patients	  provided	  written	  informed	  
consent	  at	  the	  time	  of	  recruitment.	  
	  
The	  biobank	  was	  established	  in	  October	  2016,	  and	  patient	  recruitment	  is	  ongoing.	  For	  
this	  project,	  data	  collected	  up	  to	  September	  2018	  was	  utilised.	  	  
	  
Demographic	   patient	   data	   such	   as	   gender,	   ethnicity,	   age	   at	   diagnosis,	   presenting	  
symptoms,	  medical	   comorbidities	   and	   current	  medication	  was	   collected.	   	  Diagnostic	  
information	  such	  as	  endoscopic	  findings,	  biopsy	  results,	  staging	  CT	  and	  MRI	  results,	  and	  
surgical	   information	   such	   as	   operation	   details	   and	   pathological	   findings	   were	   also	  
noted.	  Study	  data	  was	  collected	  and	  managed	  using	  REDCap	  electronic	  data	  capture	  
tools	  hosted	  by	  Otago	  University	  (65).	  	  
	  
Patients	  who	  were	  included	  in	  the	  Biobank	  were	  over	  the	  age	  of	  18	  and	  diagnosed	  with	  
CRC	  on	  endoscopy	  at	  Wellington	  Hospital,	  or	  they	  were	  referred	  to	  Wellington	  Hospital	  
from	  Hutt	  Valley	  and	  Wairarapa	  Hospitals.	  
	  
Exclusion	  criteria	  were;	  patients	  who	  had	  care	  transferred	  to	  a	  private	  hospital,	  patients	  
who	   had	   more	   than	   one	   concurrent	   malignancy,	   those	   who	   had	   malignant	   polyps	  
removed	   endoscopically	   on	   presentation,	   patients	   under	   the	   age	   of	   18,	   those	   who	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underwent	   emergency	   surgery,	   and	   finally	   those	   who	   had	   significant	   cognitive	  
impairment	  and	  were	  not	  able	  to	  provide	  informed	  consent.	  	  
	  
Patient	  recruitment	  and	  sample	  collection	  was	  carried	  out	  by	  a	  team	  of	  researchers	  at	  
the	  University	  of	  Otago.	  Recruitment	  involved	  identification	  of	  patients,	  consent,	  data	  
entry,	  database	  audit,	  blood	  collection,	  and	  assistance	  with	  collecting	  tissue	  at	  time	  of	  
surgery.	  Patients	  suitable	  for	  recruitment	  were	  identified	  from	  MDMs,	  general	  surgical	  
outpatient	   clinics	   and	   elective	   theatre	   lists.	   The	   author	   recruited	   patients	   between	  
December	  2017	  and	  June	  2018.	  
	  
2.1.2	  Patient	  selection	  
From	  the	  Colorectal	  Biobank,	  patients	  with	  Stage	  II	  and	  Stage	  III	  rectal	  cancer	  who	  had	  
neoadjuvant	  treatment	  were	  identified	  for	  this	  study.	  Patients	  were	  enrolled	  at	  the	  time	  
of	  diagnosis	  of	  rectal	  cancer,	  prior	  to	  surgery.	  The	  decision	  as	  to	  whether	  patients	  would	  
undergo	  either	  short	  or	  long	  course	  neoadjuvant	  therapy	  was	  made	  at	  the	  Wellington	  
Hospital	  Colorectal	  Multi-­‐Disciplinary	  Meeting.	  	  
	  
Control	  patients	  were	  selected	  via	  elective	  colonoscopy	   lists.	  Selected	  patients	  were	  
chosen	  to	  age	  match	  the	  CRC	  patients.	  Consent	  was	  obtained	  prior	  to	  endoscopy.	  All	  
control	  patients	  were	  symptomatic	  of	  either	  change	  in	  bowel	  habit,	  anaemia,	  or	  overt	  
rectal	  bleeding.	  To	  be	  included	  as	  a	  control,	  the	  resulting	  endoscopy	  was	  required	  to	  be	  
normal	  with	  no	  pathological	  findings	  of	  colorectal	  cancer,	  Ulcerative	  Colitis,	  or	  Crohn’s	  
disease.	  Grossly	  normal	  endoscopy	  findings	  with	  abnormal	  biopsies	  were	  considered	  a	  
reason	  for	  exclusion	  (e.g.	  ileitis).	  	  
	  
2.2	  Sample	  collection	  
Patients	  undergoing	  short	  course	  neoadjuvant	  treatment	  typically	  received	  25	  Gy	  in	  5	  
fractions.	   They	   then	  underwent	  early	   surgery,	  within	  3-­‐7	  days	  of	   finishing	   radiation.	  
Patients	   undergoing	   long	   course	   chemoradiation	   generally	   received	   50.4	   Gy	   in	   28	  
fractions	  over	  6	  weeks	  with	  concurrent	  oral	  Capecitabine	  825	  mg/m2	  twice	  daily.	  They	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then	  underwent	  surgery,	  typically	  within	  6-­‐8	  weeks	  of	  finishing	  neoadjuvant	  treatment	  
(Figure	  1).	  Venous	  blood	  samples	  were	  donated	  at	  the	  time	  of	  recruitment	  (Timepoint	  
A)	  and	  again	  after	  completing	  neoadjuvant	  therapy,	  prior	  to	  surgery	  (Timepoint	  B).	  	  For	  
short	  course	  neoadjuvant	  patients,	  blood	  was	  drawn	  on	  the	  day	  of	  surgery	  prior	  to	  any	  
anesthetic	  agent	  being	  given.	  For	  long	  course	  neoadjuvant	  patients,	  blood	  was	  drawn	  




Figure	  1	  Typical	  time	  course	  structure	  for	  (A)	  short	  course	  and	  (B)	  long	  course	  
neoadjuvant	  therapy	  
	  
Blood	   samples	   were	   obtained	   from	   patients	   at	   the	   abovementioned	   time	   points.	  
Twenty	  millilitre	  venous	  blood	  specimens	  were	  collected	  using	  a	  21G	  BDTM	  vacutainer	  
blood	   collection	   set	   into	   sodium	   citrate	   collection	   tubes	   (3.2%,	   0.109	   M)	   then	  
centrifuged	  within	  30	  minutes	  of	  withdrawal	  at	  2,000	  g	  for	  10	  minutes	  to	  separate	  blood	  
into	  plasma	  and	  serum.	  Plasma	  samples	  were	  then	  stored	  in	  a	  -­‐80°C	  freezer	  in	  multiple	  
aliquots.	   Venous	   blood	  was	   also	   collected	   into	   EDTA	   tubes	   and	   SST	   II	   Gel	   tubes	   for	  
biochemistry	  and	  hematological	  tests	  by	  the	  hospital	  laboratory.	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2.3	  Quantitative	  PCR	  
2.3.1	  Sample	  preparation	  and	  RNA	  extraction	  
Plasma	  samples	  were	  thawed	  at	  room	  temperature	  then	  centrifuged	  at	  1500	  g	  for	  10	  
minutes	  to	  remove	  any	  remaining	  cell	  or	  platelet	  debris.	  RNA	  was	  extracted	  starting	  
with	  300	  µL	  of	  plasma	  using	  the	  miRNeasy	  Serum/Plasma	  Advanced	  Kit	  using	  RNeasy	  
UCP	  MinElute	  columns	  (Qiagen)	  according	  to	  the	  manufacturer’s	  instructions.	  	  
	  
During	   the	   lysis	   step,	   the	   samples	   were	   spiked	   with	   an	   exogenous	   miRNA	   as	   an	  
extraction	   efficiency	   measure,	   using	   50	   fmol	   cel-­‐miR-­‐39-­‐3p	   spike	  
(5'UCACCGGGUGUAAAUCAGCUUG).	  
	  
The	  final	  product	  was	  eluted	  in	  30	  µL	  of	  nuclease-­‐free	  water	  and	  stored	  at	  -­‐80°C.	  	  
	  
2.3.2	  Reverse	  transcription	  	  
An	  LNA-­‐based	  reverse	  transcription	  system	  -­‐	  miRCury	  LNA	  RT	  kit	  (Qiagen)	  was	  used	  to	  
synthesise	  cDNA,	  using	  2	  µL	  of	  RNA	  for	  each	  sample.	   	  Reverse	  transcription	  (RT)	  was	  
performed	  according	  to	  the	  manufacturer’s	  protocol.	  The	  RT	  reaction	  was	  as	  follows;	  
incubation	   at	   42°C	   for	   60	   minutes,	   heat	   inactivation	   at	   95°C	   for	   5	   minutes,	   then	  
immediately	  cooled	  to	  4°C.	  Samples	  were	  then	  stored	  at	  -­‐20°C.	  	  
	  
2.3.3	  Quantitative	  PCR	  
cDNA	  samples	  from	  the	  above	  RT	  reaction	  were	  diluted	  1:2	  with	  nuclease-­‐free	  water.	  
Semi-­‐quantitative	  real-­‐time	  PCR	  was	  then	  performed	  with	  the	  SYBR	  Green	  PCR	  master	  
mix	  (ExiLENT,	  Exiqon)	  on	  a	  Corbett	  RotorGene	  6000	  with	  miRCURY	  LNA	  PCR	  primer	  sets	  
specific	  for	  hsa-­‐miR-­‐21-­‐5p,	  hsa-­‐miR-­‐29a-­‐3p,	  hsa-­‐miR-­‐143-­‐3p,	  hsa-­‐miR-­‐145-­‐5p	  (Table	  4).	  
Control	   primer	   sets	   were	   cel-­‐miR-­‐39-­‐3p	   (exogenous	   control)	   and	   hsa-­‐miR-­‐345-­‐5p	  
(endogenous	   control).	   The	   total	   reaction	   volume	   of	   each	   sample	   was	   10µL,	   which	  
included	  1	  µL	  of	  diluted	  cDNA.	  Negative	   reactions	  containing	  water	   instead	  of	  cDNA	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were	  included	  in	  every	  experiment.	  All	  reactions	  were	  performed	  in	  duplicate	  and	  CT	  
values	  within	  0.5	  were	  considered	  acceptable.	  The	   following	  cycling	  conditions	  were	  
utilised:	  95°C	  for	  10	  minutes,	  followed	  by	  40	  cycles	  of	  95°C	  for	  10	  s,	  and	  60	  °C	  for	  1	  min.	  	  
	  
Table	  3	  Primers	  used	  for	  quantitative	  PCR	  
Primer	  target	   miRNA	  sequence	  5'-­‐3'	  -­‐	  Forward	  
cel-­‐miR-­‐39-­‐3p	  spike	   5'UCACCGGGUGUAAAUCAGCUUG	  
miR-­‐21-­‐5p	   5'UAGCUUAUCAGACUGAUGUUGA	  
mirR-­‐29a-­‐3p	   5'UAGCACCAUCUGAAAUCGGUUA	  
miR-­‐143-­‐3p	   5'UGAGAUGAAGCACUGUAGCUC	  
miR-­‐145-­‐5p	   5'GUCCAGUUUUCCCAGGAAUCCCU	  
miR-­‐345-­‐5p	   5'GCUGACUCCUAGUCCAGGGCUC	  
	  
Melt	  curve	  analysis	  was	  conducted	  at	   the	  end	  of	  cycles	   to	  analyse	   the	  purity	  of	  PCR	  
products.	  This	  consisted	  of	  increasing	  the	  temperature	  from	  50°C	  -­‐	  99°C,	  rising	  by	  1°C	  
each	  step	  every	  5	  seconds.	  As	  the	  temperature	  of	  the	  reaction	  rises,	  double	  stranded	  
DNA	  melts	  apart	  at	  a	  specific	  temperature	  depending	  on	  the	  sequence,	  resulting	  in	  a	  
reduction	  in	  fluorescent	  signal	  from	  intercalated	  SYBR	  green.	  This	  is	  then	  graphed	  as	  a	  
first	  derivative	  of	  relative	  fluorescence	  units	  over	  temperature	  vs	  temperature	  of	  the	  
reaction	  mixture.	   Specific	   PCR	  products	   should	  produce	  a	  distinct	  peak	   in	   the	  graph	  
(Figure	  2).	  	  
	  
Expression	   levels	   of	  miRNA	  were	   quantified	   using	   the	   Rotor-­‐Gene	   software	   version	  
1.7.75.	  Cycle	  thresholds	  were	  set	  to	  0.09767	  across	  all	  samples	  (Figure	  2).	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Figure	  2	  Representative	  data	  from	  quantitative	  PCR	  experiments	  	  
(A-­‐G)	  Representative	  trace	  images	  (left)	  and	  melt	  curve	  profiles	  (right)	  for	  (A)	  miR-­‐21,	  
(B)	  miR-­‐29a,	  (C)	  miR-­‐143,	  (D)	  miR-­‐145,	  (E)	  miR-­‐345,	  (F)	  cel-­‐miR-­‐39	  (G)	  negative	  water	  
controls.	  All	  samples	  were	  run	  in	  duplicate	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2.4	  Tumour	  specimens	  and	  pathologic	  response	  grading	  
Surgical	   specimens	   were	   analysed	   by	   trained	   Pathologists	   at	   Wellington	   Hospital.	  	  
Pathological	  staging	  was	  performed	  using	  the	  AJCC	  TNM	  classification	  (66).	  This	  data	  
was	  available	  via	  the	  Wellington	  Hospital	  medical	  records.	  For	  patients	  who	  underwent	  
short	  course	  neoadjuvant	  therapy,	  a	  single	  pathologist	  analysed	  the	  slides	  and	  graded	  
the	   pathological	   response	   using	   the	  Modified	   Ryan	   scheme	  AJCC	   8th	  edition	   tumour	  
regression	   grading	   system	   (67).	   For	   the	   patients	   who	   underwent	   long	   course	  
neoadjuvant	  therapy,	  the	  tumour	  regression	  grade	  was	  part	  of	  the	  synoptic	  pathology	  
report.	  Patients	  that	  had	  a	  score	  of	  0,	  or	  1,	  were	  considered	  to	  have	  a	  “good”	  response,	  
and	  those	  with	  a	  score	  of	  2	  or	  3	  were	  considered	  to	  have	  a	  “bad”	  response	  (Table	  5).	  	  
	  
Table	  4	  Modified	  Ryan	  Tumour	  Regression	  Grading	  system	  
Responder	   TRG	  Score	   	  	  
"Good"	   0	   No	  viable	  cancer	  cells,	  complete	  response	  
	   I	   Single	  cells	  or	  small	  groups	  of	  cancer	  cells	  
"Bad"	   2	  
Residual	  cancer	  with	  evident	  tumour	  regression	  but	  more	  than	  
single	  cells	  or	  small	  groups	  of	  cancer	  cells	  
	   3	   Extensive	  residual	  cancer	  with	  no	  evident	  tumour	  regression	  
	  
	  
2.5	  Statistical	  analysis	  
All	   statistical	   analyses	  were	  performed	  using	  GraphPad	  Prism	  version	  7.00	   software.	  
Results	  were	  expressed	  as	  mean	  ±	  standard	  deviation.	  For	  comparisons	  of	  numerical	  
data,	  either	  paired	  or	  unpaired	  t	  tests	  were	  used.	  Comparisons	  of	  categorical	  data	  were	  
analysed	  using	  χ2	  tests.	  Values	  of	  p	  <	  0.05	  were	  considered	  statistically	  significant.	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The	  suitability	  of	  the	  housekeeper	  control	  primers	  (endogenous	  marker	  miR-­‐345	  and	  
exogenous	  cel-­‐miR-­‐39)	  was	  evaluated	  by	  comparing	  the	  raw	  CT	  values	  of	  the	  control	  
patients	  vs	  the	  cancer	  patients,	  and	  then	  the	  pre	  treatment	  vs	  post	  treatment	  values.	  
Raw	  CT	  values	  were	  of	  Gaussian	  distribution.	  Unpaired	  t	  tests	  were	  performed.	  	  
	  
The	  relative	  expression	  values	  of	  target	  miRNAs	  (miR-­‐21,	  miR-­‐29a,	  miR-­‐143,	  and	  miR-­‐
145)	  were	  calculated	  using	  the	  2-­‐ΔΔCt	  method	  (68).	  To	  calculate	  ΔCT	  the	  geometric	  mean	  
values	  of	  the	  housekeeper	  miRNA	  was	  subtracted	  from	  the	  average	  ΔCT	  value	  of	  the	  
miRNA	  of	   interest.	  ΔΔCT	  was	  calculated	  by	   subtracting	   the	  average	  ΔCT	  value	  of	   the	  
control	  group	  from	  the	  group	  of	  interest.	  Unpaired	  t	  tests	  were	  performed	  to	  compare	  
target	  miRNA	  relative	  expression	  means.	  	  
	  
When	  looking	  at	  paired	  samples	  pre	  and	  post	  neoadjuvant	  therapy,	  raw	  CT	  minus	  the	  
average	   of	   the	   housekeepers	   (2-­‐ΔCt)	   was	   used.	   Paired	   t	   tests	   were	   performed	   for	  
statistical	  analyses.	  	  To	  compare	  fold	  change	  in	  relative	  expression,	  ΔCT	  of	  target	  miRNA	  
from	  samples	  prior	  to	  neoadjuvant	  therapy	  was	  subtracted	  from	  ΔCT	  post	  therapy	  and	  
then	  logged.	  Again,	  paired	  t	  tests	  were	  then	  performed	  for	  statistical	  analysis.	  	  
	  
Correlation	  of	  miRNA	  raw	  CT	  values	  were	  calculated	  using	  the	  Pearson	  calculation	  for	  r.	  
The	   Pearson	   calculation	  was	   also	   used	   to	   analyse	   the	   correlation	   of	  miRNA	   relative	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Chapter	  3:	  	  
Results	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3.1	  Patient	  demographics	  
3.1.1	  Colorectal	  Biobank	  	  
From	  October	  2016	  to	  September	  2018,	  a	  total	  of	  195	  patients	  had	  been	  recruited	  to	  
the	  Colorectal	  Cancer	  Biobank.	  Of	  the	  total	  Biobank	  patients,	  the	  average	  patient	  age	  
was	   68.0	   years	   (range	   27-­‐88	   years).	   The	   majority	   of	   patients	   are	   of	   New	   Zealand	  
European	   ethnicity	   (86.3%),	   followed	   by	   Māori	   ethnicity	   (5.3%).	   Of	   these,	   23	   are	  
“healthy”	  control	  patients	  who	  have	  no	  evidence	  of	  CRC	  detected	  on	  endoscopy.	  The	  
remaining	  171	  patients	  have	  CRC,	  of	  which	  63	  have	  rectal	  cancer	  (32%).	  Forty-­‐one	  of	  
the	   patients	   with	   rectal	   cancer	   have	   Stage	   2	   or	   Stage	   3	   disease	   and	   underwent	  
neoadjuvant	  treatment	  as	  recommended	  by	  the	  Colorectal	  MDM,	  making	  them	  eligible	  
for	  this	  study.	  Comparing	  this	  to	  New	  Zealand	  (NZ)	  data,	  the	  proportion	  of	  patients	  with	  
rectal	  cancer	   in	  our	  Biobank	   is	  higher	  (32%)	  than	  that	  described	  in	  the	  PIPER	  project	  
(24%)(7).	  Again,	  regarding	  the	  PIPER	  data,	  the	  majority	  of	  patients	  were	  NZ	  European	  
ethnicity,	  followed	  by	  Māori	  ethnicity	  (8%).	  	  
	  
3.1.2	  Rectal	  cancer	  patients	  
From	  the	  CRC	  Biobank	  patients,	  a	  total	  of	  53	  patients	  were	  included	  in	  this	  neoadjuvant	  
study	  across	  two	  groups;	  control	  patients	  (n	  =	  19)	  and	  rectal	  cancer	  patients	  (n	  =	  34).	  Of	  
the	   34	   patients	  with	   rectal	   cancer,	   16	   underwent	   SCR	   neoadjuvant	   therapy,	   and	   18	  
underwent	   LCCR	   therapy	   (Table	   6).	   Two	   patients	   did	   not	   proceed	   to	   surgery	   after	  
neoadjuvant	  therapy,	  one	  due	  to	  frailty,	  and	  one	  patient	  declined	  surgical	  intervention,	  
therefore	  surgical	  specimens	  were	  not	  available	  for	  these	  patients.	  	  
	  
Seven	  rectal	  cancer	  patients	  were	  excluded	  from	  this	  study	  due	  to	  the	  following:	  care	  
transferred	  to	  a	  private	  hospital	  (2),	  the	  patient	  was	  deemed	  unfit	  for	  major	  abdominal	  
surgery	  (2),	  post	  operative	  pathology	  specimen	  benign	  (1),	  technical	  exclusion	  (RNA	  not	  
able	  to	  be	  extracted	  from	  plasma)	  (1),	  and	  one	  patient	  who	  had	  a	  pelvic	  lymph	  node	  
radiated	  rather	  than	  tumour.	  One	  control	  patient	  was	  excluded	  from	  this	  study	  due	  to	  
the	  finding	  of	  terminal	  ileitis	  on	  endoscopy	  biopsy.	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Of	  the	  16	  patients	  who	  underwent	  SCR,	  one	  did	  not	  have	  a	  blood	  sample	  from	  prior	  
neoadjuvant	   therapy	   starting	   (Timepoint	   A	   -­‐	   Figure	   1).	   Of	   the	   18	   patients	   who	  
underwent	  LCR,	  four	  did	  not	  have	  a	  blood	  sample	  at	  Timepoint	  A.	  These	  patients	  were	  
not	  used	  for	  pre/post	  matched	  sample	  analysis	  or	  for	  analysis	  of	  response	  to	  treatment.	  
	  
The	  mean	  age	  at	  diagnosis	  for	  the	  rectal	  cancer	  patients	  was	  63.55	  (±13.9)	  years.	  The	  
mean	  age	  of	  the	  SCR	  patients	  was	  significantly	  higher	  than	  for	  the	  LCCR	  patients,	  70.6	  
(±9.9)	  years	  vs	  57.3	  (±13.9)	  years	  respectively,	  p	  =	  0.003	  (Table	  6).	  When	  comparing	  to	  
the	  general	  NZ	  population,	   the	  mean	  age	  of	  patients	  with	  rectal	  cancer	   in	  the	  PIPER	  
study	  was	  71.4	  (±12.2)	  years	  and	  the	  majority	  of	  patients	  were	  male	  (62.5%).	  Only	  a	  
third	   of	   the	   patients	   in	   the	   PIPER	   study	  were	   completely	   staged,	   so	   it	   is	   difficult	   to	  
compare	  the	  stage	  of	  presentation	  to	  our	  patients,	  however	  they	  were	  able	  to	  state	  
76%	  of	  their	  patients	  had	  stage	  I-­‐III	  disease(7).	  The	  majority	  of	  patients	  in	  our	  study	  had	  
stage	  III	  disease	  (n	  =	  25).	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Table	  5	  Rectal	  cancer	  patient	  demographics	  
	  	   Controls	   Short	  course	   p	   Long	  course	   p	  
Total	  (n)	   19	   16	   	   18	   	  	  
	   	   	   	   	   	  	  
Mean	  age	  at	  diagnosis	  (Std.	  dev)	   68.2	  (11.5)	   70.6	  (9.9)	   0.56	   57.3	  (13.9)	   0.01	  
	  	   	   	   	   	   	  	  
Gender	  (%)	   	   	   	   	   	  	  
Female	   12	  (63.2)	   7	  (43.8)	   0.25	   9	  (50)	   0.42	  
Male	   7	  (36.8)	   9	  (56.2)	   	   9	  (5)	   	  	  
	  	   	   	   	   	   	  	  
Ethnicity	  (%)	   	   	   	   	   	  	  
NZ	  European	   19	  (100)	   13	  (81.3)	   	   13	  (72.2)	   	  	  
Maori	   	   2	  (12.5)	   	   4	  (22.2)	   	  	  
Other	   	   1	  (6.2)	   	   1	  (5.5)	   	  	  
	  	   	   	   	   	   	  	  
Preoperative	  radiological	  stage	  (n)	  	   	   	   	   	  	  
1	  &2	   	   8	   	   1	   	  	  
3	   	  	   8	   	  	   17	   	  	  
	  Age	  is	  expressed	  as	  mean	  +/-­‐	  standard	  deviation.	  Pre-­‐operative	  radiological	  stage	  is	  based	  on	  
staging	  pelvic	  MRI	  radiology	  reporting.	  
	  
The	  time	  from	  completion	  of	  neoadjuvant	  therapy	  to	  the	  day	  of	  surgery	  was	  calculated	  
for	   each	   patient.	   In	   the	   SCR	   group,	   one	   patient	   had	   a	  markedly	   extended	   delay	   to	  
surgery	  after	  completing	  neoadjuvant	  treatment	  of	  47	  days.	  This	  was	  a	  planned	  delay	  
and	  discussed	  in	  the	  Colorectal	  MDM	  as	  the	  patient	  was	  not	  felt	  to	  be	  able	  to	  withstand	  
LCCR	  due	  to	  frailty.	  With	  this	  patient	  excluded,	  the	  average	  time	  to	  surgery	  after	  SCR	  
was	  3.43	  (±1.05)	  days.	  In	  the	  LCCR	  group,	  the	  average	  time	  to	  surgery	  after	  completing	  
LCCR	  was	  51.87	  (±7.40)	  days.	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3.2	  Quality	  control	  of	  qPCR	  
The	   relative	   expression	   of	   miRNA	   in	   plasma	   were	   analysed	   using	   RT-­‐qPCR.	   First,	  
endogenous	  miR-­‐345	   and	   exogenous	   cel-­‐miR-­‐39	  were	   compared	   across	   the	   groups.	  
There	  was	  no	  statistical	  difference	  in	  the	  mean	  raw	  CT	  for	  either	  miR-­‐345	  or	  cel-­‐miR-­‐39	  
when	   comparing	   those	   in	   control	   patients	   with	   those	   with	   cancer	   (Figure	   3).	  
Comparisons	  were	  also	  performed	  for	  pre	  and	  post	  treatment,	  and	  for	  the	  geometric	  
means	  of	  miR-­‐345	  and	  cel-­‐miR-­‐39	  together	  (Figure	  3).	  Again,	  there	  was	  no	  significant	  
differences,	   and	   thus	   these	   two	  miRNA	   could	   be	   used	   as	   housekeepers	   for	   further	  
analysis.	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Figure	  3.	  Analysis	  of	  endogenous	  and	  exogenous	  housekeepers.	  	  
A)	  Raw	  CT	  values	  for	  cel-­‐miR-­‐39	  for	  the	  control	  vs.	  cancer	  groups	  (p	  =	  0.7305),	  B)	  Raw	  CT	  
values	  for	  miR-­‐345	  for	  control	  vs	  cancer	  groups	  (p	  =	  0.6056),	  C)	  Raw	  CT	  values	  for	  cel-­‐
miR-­‐39	  pre	  and	  post	  treatment	  (p	  =	  0.1189)	  D)	  Raw	  CT	  values	  for	  miR-­‐345	  for	  the	  pre	  
and	  post	   treatment	  groups	   (p	  =	  0.2770),	  E)	  Geometric	  means	  comparing	  controls	  vs.	  
cancer	   patient	   groups	   (p	   =	   0.9282),	   F)	   Geometric	   means	   comparing	   pre	   and	   post	  
neoadjuvant	  therapy	  (p	  =	  0.1292).	  Tx	  =	  treatment.	  All	  means	  compared	  using	  unpaired	  
t	  test.	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3.3	  MicroRNA	  expression	  in	  rectal	  cancer	  patients	  vs.	  controls	  
Prior	   research	  has	  demonstrated	   that	  miR-­‐21	  and	  miR-­‐29a	  are	  upregulated	   in	   rectal	  
cancer	  tissue,	  whilst	  miR-­‐145	  is	  downregulated	  in	  rectal	  cancer	  tissue	  and	  miR-­‐143	  is	  
down	   regulated	   in	   colon	   cancer	   tissue	   (55).	   Studies	   have	   shown	   similar	   changes	   in	  
expression	  in	  plasma	  which	  seem	  to	  be	  specific	  to	  cancer	  stage	  (58,	  69,	  70).	  Therefore,	  
we	   compared	   the	   relative	   expression	   of	   miR-­‐21,	   miR-­‐29a,	   miR-­‐143	   and	   miR-­‐145	   in	  
plasma	   for	   the	   control	   patients	   vs.	   stage	   II/III	   rectal	   cancer	   patients	   (prior	   to	  
neoadjuvant	   therapy)	   to	   determine	   the	   difference	   in	   expression.	   There	   was	   no	  
statistically	   significant	   change	   in	   relative	   expression	   between	   the	   control	   group	   vs.	  
cancer	  patients	  (Figure	  4).	  miR-­‐21	  was	  overexpressed	  compared	  to	  the	  average	  of	  the	  
controls	  in	  35%	  of	  patients	  and	  there	  was	  one	  patient	  with	  very	  high	  expression.	  miR-­‐
143	   and	   miR-­‐145	   were	   overexpressed	   in	   21%	   of	   patients,	   whilst	   miR-­‐29a	   was	  
overexpressed	   in	   17%	   of	   patients.	   When	   looking	   at	   miR-­‐143	   and	   miR-­‐145	   relative	  
expression	  in	  the	  controls,	  there	  was	  one	  patient	  with	  very	  high	  expression	  of	  both	  of	  
these	  miRNAs.	  	  
	  
3.4	  The	  effect	  of	  neoadjuvant	  therapy	  on	  circulating	  target	  miRNA	  expression	  	  
Pre	  and	  post	  neoadjuvant	  treatment	  miRNA	  relative	  expression	  levels	  (paired	  samples)	  
were	   analysed	   to	   determine	  whether	   there	  was	   a	   treatment	   effect	  which	  would	   be	  
clinically	  relevant.	  There	  was	  a	  statistically	  significant	   increase	  in	  mIR-­‐143	  after	  short	  
course	   radiation.	   There	   were	   no	   other	   statistically	   significant	   changes	   in	   relative	  
expression	  (Figure	  5).	  The	  average	  fold	  changes	  in	  expression	  were	  also	  analysed.	  For	  
miR-­‐21	  the	  average	  fold	  change	  after	  SCR	  was	  1.36	  (±1.45),	  and	  after	  LCCR	  was	  1.42	  
(±1.06).	  MiR-­‐29a	   had	   an	   average	   fold	   change	   of	   1.16	   (±	   0.967)	   after	   SCR	   and	   1.152	  
(±0.79).	  For	  miR-­‐143	  the	  average	  fold	  change	  after	  SCR	  was	  2.00	  (±1.53)	  and	  after	  LCCR	  
was	  3.04	  (±5.26).	  The	  average	  fold	  change	  was	  the	  greatest	  for	  miR-­‐145	  which	  after	  SCR	  
was	  5.2	  (±8.409)	  and	  after	  LCCR	  3.64	  (±9.01).	  Unpaired,	  group	  averages	  pre	  and	  post	  
treatment	  were	  also	   analysed	  and	   there	  was	  no	   statistically	   significant	  difference	   in	  
relative	  expression.	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Figure	  4	  Relative	  expression	  of	  target	  miRNA,	  comparing	  control	  patients	  to	  those	  with	  
cancer.	  
A)	  miR-­‐21	  (p	  =	  0.5036),	  B)	  miR-­‐29a	  (p	  =	  0.7260),	  C)	  miR-­‐143	  (p	  =	  0.2433),	  D)	  miR-­‐145	  
(p	  =	  0.5965).	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Figure	  5	  Target	  miRNA	  relative	  expression	  for	  paired	  data	  comparing	  pre	  and	  post	  
neoadjuvant	  therapy.	  
A)	  miR-­‐21	  relative	  expression	  after	  SCR	  (p	  =	  0.3289)	  and	  LCCR	  (p	  =	  0.8794).	  B)	  Relative	  
expression	  of	  miR-­‐29a	  after	  SCR	  (p	  =	  0.2470)	  and	  	  LCCR	  (p	  =	  0.8626)	  for	  miR-­‐29a,	  C)	  
miR-­‐143	  relative	  expression	  was	  significantly	  different	  after	  SCR	  (p	  =	  0.0282)	  but	  not	  
after	  LCCR	  (p=	  0.4719).	  D)	  miR-­‐145	  relative	  expression	  after	  SCR	  (p	  =	  0.1860)	  and	  LCCR	  
(p	  =	  0.5838).	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3.4	  miRNA	  correlations	  
Raw	  miRNA	  CT	  values	  for	  each	  patient	  (at	  Timepoint	  A)	  were	  analysed	  using	  Pearson’s	  
correlation	  (Figure	  6).	  The	  strongest	  correlation	  was	  between	  miR-­‐21	  and	  miR-­‐29a	  (r	  =	  
0.8107),	  then	  between	  miR-­‐29a	  and	  miR-­‐143	  (r	  =	  0.7219),	  followed	  by	  miR-­‐21	  vs	  miR-­‐
143	  (r	  =	  0.7044),	  miR-­‐21	  vs	  miR-­‐145	  (r	  =	  0.6805),	  miR-­‐29a	  vs	  miR-­‐145	  (r	  =	  0.5371),	  and	  
lastly	  the	  weakest	  correlation	  was	  between	  miR-­‐143	  and	  miR-­‐145	  (r	  =	  0.4865).	  
	  
Due	   to	   the	   integral	   role	  of	   the	   immune	   system	   in	   the	  progression	  and	   regulation	  of	  
cancer	  growth,	  we	  evaluated	  the	  relative	  expression	  of	  the	  miRNA	  with	  NLR	  and	  CRP.	  It	  
has	  been	  previously	  reported	  that	  patients	  with	  a	  higher	  NLR	  have	  a	  lower	  rate	  of	  pCR	  
(OR	  1.72,	  95%	  CI	  1.26-­‐2.33)	  (37).	  In	  our	  study,	  the	  relative	  expression	  of	  miR-­‐21,	  miR-­‐
29a,	  miR-­‐143,	   and	  miR-­‐145	  of	   cancer	  patients	  did	  not	   correlate	  with	  patient	  NLR	  at	  
Timepoint	  A	  (Figure	  7).	  
	  
The	  relative	  expression	  of	  miR-­‐21,	  miR-­‐29a,	  miR-­‐143	  and	  miR-­‐145	  in	  cancer	  patients	  did	  
not	  correlate	  with	  CRP	  at	  Timepoint	  A.	  This	  was	   limited	  by	  the	  sensitivity	  of	  the	  CRP	  
assay	  in	  that	  all	  values	  less	  than	  three	  were	  entered	  as	  three.	  Even	  when	  only	  taking	  
into	  account	  CRP	  values	  greater	  than	  three,	  (n	  =	  12),	  there	  was	  still	  no	  correlation	  with	  
target	  miRNA	  relative	  expression.	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Figure	  6	  Correlations	  between	  miRNA	  raw	  CT	  values	  
A)	  miR-­‐21	  vs	  miR-­‐29a,	  B)	  miR-­‐29a	  vs	  miR-­‐143,	  C)	  miR-­‐21	  vs	  miR-­‐143	  D)	  miR-­‐21	  vs	  miR-­‐
145,	  E)	  miR-­‐29a	  vs	  miR-­‐145,	  and	  F)	  miR-­‐143	  and	  miR-­‐145.	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Figure	   7	   Correlation	   between	   Neutrophil:Lymphocyte	   Ratio	   (NLR)	   and	   target	  miRNA	  
expression	  
A)	  miR-­‐21	  expression	  and	  NLR	  (r	  =	  0.04897),	  B)	  miR-­‐29a	  and	  NLR	  (r	  =	  0.1074),	  C)	  miR-­‐
143	  expression	  and	  NLR	  (r	  =	  0.01653)	  ,	  D)	  miR-­‐145	  expression	  and	  NLR	  (r	  =	  -­‐0.2627).	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Preoperative	  CEA	  levels	  in	  serum	  have	  previously	  been	  reported	  to	  correlate	  with	  miR-­‐
155	  expression	  in	  CRC	  tissue	  (Hongliang,	  Shaojun	  et	  al.	  2014).	  Whether	  or	  not	  there	  is	  
a	  relationship	  between	  our	  target	  miRNA	  expression	  in	  plasma	  and	  CEA	  is	  previously	  
unreported.	  In	  our	  study,	  the	  relative	  expression	  of	  miR-­‐21,	  miR-­‐29A,	  miR-­‐143	  and	  miR-­‐
145	  in	  cancer	  patients	  did	  not	  correlate	  with	  CEA	  levels	  at	  Timepoint	  A	  (Figure	  8).	  	  
	  
	  
Figure	  8	  Correlation	  between	  CEA	  and	  target	  miRNA	  
A)	  miR-­‐21	  and	  CEA	  (r	  =	  0.04191),	  B)	  miR-­‐29a	  and	  CEA	  (r=	  -­‐0.1335),	  C)	  miR-­‐143	  and	  CEA	  
(r	  =	  -­‐0.08281)	  or	  D)	  miR-­‐145	  and	  CEA	  (r	  =	  -­‐0.02717).	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3.5	  Tumour	  Regression	  Grading	  and	  miRNA	  relative	  expression	  
An	  aim	  of	  this	  study	  was	  to	  evaluate	  whether	  miRNA	  expression	  could	  predict	  TRG.	  Each	  
target	  miRNA	  expression	  was	  analysed	  separately	   in	  patients	  who	  underwent	  SCR	  or	  
LCCR.	  	  
	  
3.5.1	  Patients	  receiving	  SCR	  
Of	  the	  16	  short	  course	  neoadjuvant	  therapy	  patients,	  15	  proceeded	  to	  surgery	  and	  had	  
pathology	   specimens	   analysed	  with	   TRG	   reported.	  Of	   these	   patients,	   12	   showed	  no	  
response	  to	  radiation	  treatment	  (TRG	  3),	  and	  three	  showed	  some	  response	  (TRG	  2).	  No	  
patients	  had	  a	  greater	  response	  to	  treatment	  than	  TRG	  2.	  One	  patient	  did	  not	  have	  a	  
plasma	   sample	   from	   Timepoint	   A	   and	   was	   not	   used	   in	   this	   analysis.	   There	   was	   no	  
statistical	   difference	   in	   the	   relative	   expression	   of	   the	   miRNA	   between	   these	   two	  
subgroups	  of	  patients	  (Figure	  9).	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Figure	   9	   Comparison	   between	   patients	   who	   underwent	   short	   course	   neoadjuvant	  
therapy	  who	  had	  any	  response	  to	  treatment	  vs.	  no	  response	  to	  treatment.	  
A)	  miR-­‐21	  relative	  expression	  (p	  =	  0.7799),	  B)	  miR-­‐29a	  relative	  expression	  (p	  =	  0.1261),	  
C)	  miR-­‐143	  relative	  expression	  (p	  =0.7285),	  or	  D)	  miR-­‐145	  relative	  expression	  (p	  =	  
0.5234).	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3.5.2	  Long	  course	  neoadjuvant	  patients	  
Of	  the	  18	  LCR	  patients,	  four	  did	  not	  have	  preoperative	  blood	  samples	  taken	  and	  one	  did	  
not	  proceed	  to	  surgery.	  This	   left	  a	  total	  of	  13	  patients	  samples	  to	  be	  analysed	  when	  
comparing	  miRNA	  expression	  at	  Timepoint	  A	  and	  TRG.	  There	  were	  no	  patients	  with	  pCR.	  
Of	  the	  13	  patients	  who	  then	  had	  Timepoint	  A	  blood	  and	  TRG,	  3	  had	  a	  “good	  response”	  
of	  TRG	  1,	  and	  10	  had	  a	  “bad	  response”	  of	  TRG	  2	  or	  TRG	  3.	  When	  comparing	  the	  “good”	  
vs.	   “bad”	   response	   sub	  groups,	   there	  was	  no	   statistical	  difference	   in	  miRNA	   relative	  
expression	   (Figure	  10).	  Patient	   samples	  with	  a	  “good”	  and	  “bad”	   response	  were	  not	  
further	  analysed	  comparing	  pre	  and	  post	  SCR	  and	  LCCR	  as	  planned	  due	  to	  the	  very	  low	  
numbers.	  For	  example,	  there	  were	  	  only	  two	  patients	  in	  the	  “good”	  response	  group	  with	  
paired	  samples	  making	  this	  data	  insignificant.	  	  
	  
Given	  that	  previous	  research	  has	  demonstrated	  increased	  rates	  of	  tumour	  regression	  
with	  prolonging	  the	  time	  delay	  from	  radiotherapy	  to	  surgery,	  it	  was	  important	  to	  review	  
whether	  this	  impacted	  on	  TRG	  in	  our	  study.	  Regarding	  time	  from	  finishing	  neoadjuvant	  
therapy	   to	  date	  of	   surgery,	   the	  patients	  were	  again	  divided	   into	   the	  subgroups	   ‘Any	  
response’	  and	  ‘no	  response’	  for	  SCR	  and	  ‘good	  response’	  and	  ‘bad	  response’	  for	  LCR.	  
The	   average	   time	   to	   surgery	   in	   these	   two	   groups	  was	   compared	   and	   there	  was	   no	  
difference	  between	  them	  (for	  LCR;	  50.7	  ±	  3.3	  days	  for	  ‘good’	  response,	  and	  50.1	  ±	  8.4	  
for	  ‘bad’	  response,	  p	  =	  0.9082).	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Figure	  10	  	  Comparison	  of	  miRNA	  relative	  expression	  prior	  to	  LCCR	  neoadjuvant	  therapy	  
in	  “good”	  and	  “bad”	  responders	  
A)	  miR-­‐21	  relative	  expression	  (p	  =	  0.7311),	  B)	  miR-­‐29a	  relative	  expression	  (p	  =	  0.4917),	  
C)	  miR-­‐143	  relative	  expression	  (p	  =0.6133),	  or	  D)	  miR-­‐145	  relative	  expression	  (p	  =	  
0.8261).	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Chapter	  4:	  	  
Discussion	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This	   study	   has	   investigated	   circulating	   miRNA	   levels	   in	   patients	   who	   have	   locally	  
advanced	   rectal	   cancer	   and	   have	   undergone	   neoadjuvant	   therapy.	   The	   aims	   of	   this	  
study	  were	  to	  determine	  if	  patients	  with	  stage	  II/III	  rectal	  cancer	  had	  altered	  expression	  
of	  the	  target	  miRNAs	  compared	  to	  controls,	  and	  to	  ascertain	  if	  these	  miRNA	  levels	  in	  
plasma	  prior	  to	  treatment	  can	  predict	  response	  to	  SCR	  and	  LCCR	  therapy,	  or	  if	  changes	  
in	  levels	  in	  response	  to	  neoadjuvant	  therapy	  occur	  as	  markers	  of	  therapeutic	  response.	  	  
	  
The	  standard	  management	  for	   locally	  advanced	  rectal	  cancer	   is	  neoadjuvant	  therapy	  
followed	  by	  TME	  surgical	  resection,	  but	  the	  response	  to	  therapy	  is	  varied.	  Whilst	  there	  
is	  potential	  benefit	   to	  gaining	  complete	   response,	  on	   the	  other	  hand,	   therapy	   is	  not	  
without	  risk.	  Patients	  may	  suffer	  a	  number	  of	  adverse	  side	  effects	  from	  treatment,	  and	  
of	  course	  a	  delay	  to	  surgery.	  Despite	  gains	  in	  knowledge	  regarding	  the	  detection	  and	  
management	  of	  rectal	  cancer,	  we	  are	  still	  not	  able	  to	  predict	  which	  patients	  will	  benefit	  
from	  neoadjuvant	   therapy.	  Given	   the	  potential	   adverse	   effects,	   patients	   need	   to	  be	  
selected	  for	  optimal	  treatment	  with	  some	  certainty	  that	  they	  would	  receive	  a	  benefit.	  
The	  development	  of	   blood	  based	  biomarkers	   predictive	  of	   response	   to	  neoadjuvant	  
therapy	  would	  allow	  for	  this	  early	  in	  the	  patient’s	  treatment	  pathway.	  Whilst	  some	  have	  
been	  proposed	  to	  date,	  none	  have	  been	  used	  in	  a	  clinical	  setting	  so	  far.	  
	  
MiRNA	  are	  an	  interesting,	  novel	  class	  of	  biomarkers	  that	  we	  have	  chosen	  to	  investigate	  
further	   due	   to	   their	   stability	   in	   biofluids	   and	   increasing	   evidence	   that	   there	   is	  
dysregulation	  in	  miRNA	  expression	  in	  cancer	  patients,	  and	  importantly	  here,	  in	  rectal	  
cancer.	  We	  have	  chosen	   four	   target	  miRNA;	  miR-­‐21,	  miR-­‐29a,	  miR-­‐143	  and	  miR-­‐145	  
because	  they	  are	  all	  dysregulated	  in	  CRC	  tissue	  and	  plasma,	  and	  miR-­‐21,	  miR-­‐143	  and	  
miR-­‐145	  have	  been	  previously	  associated	  with	  response	  to	  neoadjuvant	  therapy	  (71).	  
miR-­‐21	  and	  miR-­‐29a	  are	  reported	  to	  be	  over	  expressed	  in	  CRC	  and	  function	  as	  oncomiRs	  
(38,	   55)	   ,	   whist	  miR-­‐143	   and	  miR-­‐145	   are	   under	   expressed	   and	   function	   as	   tumour	  
suppressors	  (55).	  Importantly,	  serum	  miR-­‐143	  has	  been	  shown	  to	  have	  some	  ability	  to	  
predict	  TRG	  after	  LCR	  (47).	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In	  this	  pilot	  study	  we	  have	  found	  a	  significant	  increase	  in	  the	  relative	  expression	  miR-­‐
143	  in	  plasma	  after	  SCR.	  There	  was	  no	  difference	  in	  expression	  of	  miR-­‐21,	  miR-­‐29a,	  miR-­‐
143	   or	   miR-­‐145	   in	   patients	   with	   stage	   II	   and	   III	   rectal	   cancer	   compared	   to	   healthy	  
controls.	  There	  was	  no	  difference	  in	  expression	  of	  target	  miRNA	  in	  patients	  who	  had	  a	  
response	  to	  neoadjuvant	  therapy	  compared	  to	  those	  with	  little	  or	  no	  response.	  	  
	  
This	   study	   has	   contributed	   to	   the	   small	   existing	   pool	   of	   knowledge	   on	   the	   use	   of	  
circulating	  miRNA	   as	   predictive	   biomarkers	   for	   response	   to	   neoadjuvant	   therapy	   in	  
rectal	   cancer	  patients.	  With	   the	  data	  we	  have	  obtained	   so	   far,	   it	   is	   still	   too	  early	   to	  
determine	  absolutely	   if	  these	  miRNAs	  have	  a	  predictive	  use	  due	  to	  the	  small	  patient	  
group	  size.	  	  
	  
Rectal	  cancer	  patients	  at	  Wellington	  Hospital	  
The	   Wellington	   CRC	   biobank	   patients	   have	   a	   higher	   proportion	   of	   rectal	   cancers	  
compared	  to	  that	  reported	  in	  the	  PIPER	  project	  report	  (32%	  vs	  24%)	  (7).	  This	  is	  likely	  
because	  the	  PIPER	  project	  included	  all	  CRC	  patients	  between	  2006	  and	  2009,	  and	  recent	  
evidence	  would	  indicate	  that	  rectal	  cancer	  incidence	  is	  increasing	  in	  patients	  under	  the	  
age	  of	  50,	  with	  a	  13%	  increase	  in	  women	  and	  an	  18%	  increase	  in	  men	  per	  decade	  in	  this	  
age	  category	  (72).	  In	  addition	  to	  this,	  the	  Wellington	  biobank	  consists	  of	  mostly	  elective	  
cases	  and	  acute	  rectal	  resection	  is	  very	  uncommonly	  performed.	  	  
	  
When	  comparing	  the	  SCR	  and	  LCCR	  patient	  groups,	  there	  was	  a	  notable	  age	  difference	  
between	  the	  short	  course	  patients	  (70.6	  ±9.9	  years)	  and	  the	  long	  course	  patients	  (57.3	  
±13.9	  years).	   It	   is	   likely	  this	   is	  because	  patients	  that	  are	  older	  are	  generally	  frailer	  or	  
have	  more	  medical	  co-­‐morbidities	  and	  may	  not	  be	  able	  to	  tolerate	  LCCR,	  making	  them	  
more	  suitable	  candidates	  for	  SCR.	  	  
	  
Given	   that	   increasing	   the	   delay	   after	   neoadjuvant	   therapy	   to	   surgery	   can	   improve	  
tumour	  regression	  (73),	  it	  was	  important	  to	  determine	  the	  time	  delays	  for	  each	  patient.	  
One	   patient	   did	   have	   a	   planned,	   marked	   delay	   to	   surgery	   after	   SCR	   of	   47	   days.	  
Interestingly,	  this	  patient	  did	  not	  have	  a	  “good”	  response	  to	  SCR,	  with	  a	  TRG	  of	  2.	  There	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was	   no	   statistically	   significant	   difference	   when	   looking	   at	   the	   averages	   of	   the	   time	  
delays	  for	  the	  “good”	  and	  “bad”	  responder	  groups.	  	  
	  
miRNA	  in	  rectal	  cancer	  vs.	  controls	  
In	  this	  study,	  we	  found	  that	  there	  was	  no	  difference	  in	  relative	  expression	  of	  plasma	  
miR-­‐21,	   miR-­‐29a,	   miR-­‐143	   or	   miR-­‐145	   when	   comparing	   control	   patients	   and	   rectal	  
cancer	  patients.	  The	  current	  literature	  reports	  that	  the	  expression	  of	  miR-­‐21	  and	  miR-­‐
29a	   are	   upregulated	   in	   rectal	   cancer	   tissue,	   and	   that	   miR-­‐143	   and	   miR-­‐145	   are	  
downregulated	  in	  rectal	  cancer	  tissue	  (55).	  Plasma	  miR-­‐21	  and	  miR-­‐143	  has	  been	  shown	  
to	   be	   decreased	   in	   CRC	   patients	   compared	   to	   controls	   (69),	   and	   plasma	   miR-­‐145	  
increased	  (71).	  Huang	  et	  al.	  report	  that	  when	  specifically	  looking	  at	  plasma,	  miR-­‐29a	  is	  
upregulated	   in	   CRC	   patients	   and	   there	   is	   a	   stepwise	   increase	   in	   expression	   with	  
increasing	  TNM	  stage	  compared	  to	  controls	  (70).	  These	  authors	  looked	  at	  120	  plasma	  
samples	  from	  patients	  with	  CRC	  which	  were	  taken	  prior	  to	  surgery	  (27	  stage	  I,	  25	  stage	  
II,	  38	  stage	  III,	  and	  10	  stage	  IV).	  Despite	  reporting	  this,	  there	  is	  a	  statistical	  difference	  
when	  comparing	   control	  patients	  with	  patients	  at	  each	   stage	  of	  disease	   rather	   than	  
when	  comparing	  each	  stage	  consecutively.	  This	  group	  also	  found	  that	  miR-­‐29a	  plasma	  
levels	  dropped	  significantly	  7-­‐10	  days	  after	  surgery	  in	  a	  subgroup	  of	  20	  patients	  with	  
CRC	   (p=0.04).	   It	   is	   interesting	   to	   note	   that	   Ng	   et	   al.	   (2008)	   found	   an	   increase	   in	  
expression	  of	  both	  miR-­‐17-­‐3p	  and	  miR-­‐92	  in	  plasma	  in	  CRC	  patients	  but	  did	  not	  find	  an	  
increase	   in	  expression	  of	  miR-­‐21	  or	  miR-­‐29a	   in	  plasma.	  The	  main	   limitation	  with	  this	  
finding	  was	  that	  in	  the	  first	  step	  in	  the	  discovery	  phase	  of	  their	  study	  they	  only	  sampled	  
from	  five	  CRC	  patients	  compared	  to	  five	  healthy	  controls,	  which	  is	  a	  very	  small	  sample	  
size	  (54).	  	  
	  
It	   is	  possible	   that	  our	   study	  did	  not	   identify	   a	  difference	   in	  expression	  of	  our	   target	  
miRNA	   is	   because	  we	   excluded	   patients	  with	   stage	   IV	   disease.	  We	   have	   specifically	  
looked	  at	  stage	  II/III	  disease	  and	  levels	  of	  these	  miRNA	  are	  often	  reportedly	  higher	  in	  
stage	  IV	  disease,	  which	  could	  potentially	  explain	  not	  seeing	  a	  difference.	  In	  addition	  to	  
this,	  our	  sample	  size	  is	  small	  (n	  =	  36	  compared	  to	  n	  =	  120	  in	  the	  Huang	  study).	  At	  this	  
stage	  with	  our	  results,	  plasma	  miR-­‐21,	  miR-­‐29a,	  miR-­‐143	  and	  miR-­‐145	  expression	  levels	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prior	  to	  neoadjuvant	  therapy	  do	  not	  seem	  to	  be	  useful	  as	  discriminating	  rectal	  cancer	  
diagnostic	  tests.	  	  
	  
The	   control	   patients	  were	   19	   “healthy”	   patients	   and	   controls	   were	   confirmed	   after	  
having	   a	   normal	   colonoscopy	   with	   normal	   biopsies.	   Despite	   being	   called	   “healthy”,	  
some	  have	   underlying	   chronic	  medical	   conditions	   (for	   example	   hypertension)	  which	  
could	  affect	  target	  miRNA	  relative	  expression	  to	  some	  unknown	  extent.	  The	  number	  of	  
controls	  used	  was	  relatively	  small	  compared	  to	  previous	  studies	  on	  miRNA	  expression	  
which	  ranged	  from	  10	  to	  144	  subjects	  (58).	  	  
	  
miR-­‐143	  changes	  after	  neoadjuvant	  therapy	  
This	   study	   is	   the	   first	   to	   examine	   changes	   in	   plasma	   expression	   pre	   and	   post	  
neoadjuvant	   therapy	   of	   miR-­‐29a,	   miR-­‐143,	   miR-­‐145	   and	   miR-­‐21.	   We	   report	   a	  
statistically	  significant	  increase	  in	  relative	  expression	  of	  miRNA-­‐143	  in	  plasma	  after	  SCR	  
(Figure	  4).	  Out	  of	   the	  15	  paired	  samples,	  11	  had	  an	   increase	   in	  miR-­‐143	  expression.	  
There	  was	  no	  significant	  change	  in	  relative	  expression	  of	  miR-­‐21,	  miR-­‐-­‐29a,	  or	  miR-­‐145	  
in	  either	  LCCR	  or	  SCR	  patients.	  Publications	  so	  far	  have	  focused	  on	  miRNA	  expression	  
changes	   after	   surgery,	   but	   not	   at	   the	   time	   point	   prior	   to	   surgery	   after	   neoadjuvant	  
therapy	  except	  for	  a	  recent	  study	  looking	  at	  miR-­‐143	  in	  serum	  (47).	  It	  is	  important	  to	  
note	  that	  one	  possible	  confounder	  in	  the	  SCR	  patients	  in	  this	  study	  is	  that	  fasting	  status	  
was	  different.	  Due	  to	  the	  nature	  of	  the	  venous	  blood	  collection,	  the	  Timepoint	  B	  sample	  
is	  collected	  immediately	  prior	  to	  surgery	  when	  patients	  are	  fasted	  and	  could	  contribute	  
to	  the	  difference	  seen.	  Ideally	  this	  would	  be	  repeated	  in	  a	  larger	  group	  with	  consistent	  
fasting	  status.	  	  
	  
Toiyama	  et	  al.	  looked	  at	  miR-­‐21	  expression	  in	  CRC	  samples	  in	  186	  patients	  and	  found	  
that	  tumour	  and	  serum	  miR-­‐21	  expression	  was	  higher	  in	  larger	  tumours	  (p=0.004)	  (56).	  
The	  authors	  looked	  at	  another	  set	  of	  60	  patients	  who	  underwent	  curative	  surgery	  and	  
compared	  miR-­‐21	  levels	  pre	  and	  post	  surgery	  and	  found	  those	  with	  curative	  resections	  
had	   a	   marked	   decrease	   in	   miR-­‐21	   expression	   (p	   =	   <0.001)(56).	   We	   also	   suspect	  
circulating	  miRNA	  is	  from	  tumour	  bulk	  and	  that	  therefore,	  the	  changes	  seen	  would	  be	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expected	  to	  be	  different	   in	  studies	  reporting	  changes	  after	  surgery	  compared	  to	  our	  
study.	  We	  would	  expect	  that	  surgically	  excising	  a	  tumour	  would	  give	  different	  results	  to	  
targeting	  cells	  with	  radiotherapy,	  as	  surgery	  would	  lead	  to	  a	  rapid	  decrease	  in	  miRNA	  
expression	  and	  perhaps	   the	   increase	   in	   circulating	  miR-­‐143	   is	  due	   to	  damage	   to	   the	  
tumour	  or	  an	   inflammatory	   response	   from	  the	  radiotherapy.	  Of	  note,	  an	   increase	   in	  
miR-­‐143	   and	   other	  miRNA	   in	   peripheral	   blood	   have	   been	   reported	   after	   total	   body	  
radiotherapy	   before	   in	   patients	   with	   acute	   myeloid	   leukaemia	   (74).	   These	   findings	  
would	  also	  lead	  us	  to	  suspect	  that	  if	  there	  was	  a	  further	  delay	  after	  SCR	  we	  may	  see	  
changes	  in	  the	  other	  target	  miRNA.	   
	  
miRNA	  correlations	  with	  other	  clinical	  markers	  
The	  function	  of	  the	  immune	  response	  as	  a	  key	  factor	  in	  the	  process	  of	  cancer	  is	  an	  area	  
of	  intense	  research.	  Given	  the	  emerging	  evidence	  that	  miRNA	  have	  a	  role	  to	  play	  as	  key	  
modulators	   of	   the	   tumour	   immune	   response	   (75),	   it	   would	   seem	   appropriate	   to	  
evaluate	   for	   correlation	   between	  miRNA	   expression	   and	   inflammatory	  markers.	   For	  
example,	  miR-­‐21	  has	  a	  role	  in	  cell	  differentiation	  of	  monocytes,	  macrophages,	  T	  cells	  
and	  dendritic	  cells	  and	  is	  thought	  to	  indirectly	  target	  Interleukin-­‐6	  (IL-­‐6)	  and	  promote	  
cancer	   cell	   invasion	  and	   tumour	  progression	   (76).	   In	   this	   study,	  we	  did	  not	   find	  any	  
correlation	  between	  miRNA	  relative	  expression	  and	  NLR	  or	  CRP	  (Figure	  7	  and	  8).	  So	  far,	  
there	  are	  no	  published	  works	  on	  the	  correlation	  of	  miRNA	  and	  CRP	   in	  CRC,	  however	  
there	  is	  some	  data	  in	  studies	  of	  inflammatory	  conditions	  such	  as	  Inflammatory	  Bowel	  
Disease	  (IBD)	  and	  Rheumatoid	  Arthritis	  (RA)(77)	  (78).	  In	  RA	  patients,	  a	  change	  in	  CRP	  
after	  starting	  combination	  therapy	  for	  RA	  seems	  to	  be	  weakly	  associated	  with	  change	  
in	  miR-­‐126-­‐3p	  (r	  =	  0.349)	  and	  miR-­‐23-­‐3p	  (r	  =	  0.360)	  (77).	  It	  is	  possible	  that	  the	  reason	  
we	  did	  not	  see	  changes	  in	  circulating	  miRNA’s	  correlating	  with	  changing	  CRP	  and	  NLR	  
could	  be	  due	  to	  the	  fact	  that	  there	  is	  more	  localised	  inflammation	  within	  the	  tumour	  
microenvironment	  rather	  than	  those	  detectable	  in	  the	  peripheral	  circulation.	  	  
	  
In	   clinical	   practice	   CEA	   is	   utilised	   as	   a	   non-­‐invasive	   tool	   to	   attempt	   to	   detect	   CRC	  
recurrence	  as	  part	  of	  ongoing	  cancer	  surveillance.	  Even	  when	  used	  in	  this	  setting,	  it	  has	  
insufficient	   sensitivity	   and	   specificity	   to	   be	   used	   alone,	   and	   is	   often	   coupled	   with	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imaging	   studies.	   Some	   authors	   report	   that	   it	   could	   be	   advantageous	   to	   couple	   CEA	  
monitoring	  with	  miRNA	  tests	  when	  looking	  for	  CRC	  recurrence	  (79).	  There	  is	  a	  lack	  of	  
evidence	  that	  CEA	  can	  be	  used	  for	  prognostic	  purposes	  and	  in	  this	  study	  we	  also	  did	  not	  
find	  any	  correlation	  between	  CEA	  and	  our	  target	  miRNA	  expression	  (Figure	  9).	  	  
	  
In	  this	  study	  there	  was	  a	  strong	  correlation	  of	  raw	  Ct	  values	  of	  miR-­‐21	  and	  miR-­‐29a	  (r	  =	  
0.8107).	  There	  was	  a	  moderate	  correlation	  between	  miR-­‐29A	  and	  miR-­‐143	  (r	  =	  0.7219)	  
and	  miR-­‐21	  and	  miR-­‐143	  (r	  =	  0.7044).	  There	  was	  a	  weak	  correlation	  between	  miR-­‐143	  
and	  miR-­‐145	  (r	  =	  0.4865).	  This	  is	  important	  for	  future	  work	  after	  this	  pilot	  study	  because	  
if	  these	  miRNA	  expression	  levels	  are	  very	  closely	  correlated	  then	  they	  might	  not	  provide	  
additive	  information.	  Therefore,	  we	  may	  not	  need	  to	  measure	  all	  of	  the	  miRNA	  that	  we	  
are	   currently	   targeting.	   Correlations	   between	  miRNA	  expression	   in	   plasma	  have	  not	  
been	   reported	   previously.	   Prior	   to	   making	   these	   decisions	   however	   it	   would	   be	  
imperative	  to	  test	  this	  in	  larger	  patient	  groups	  with	  ROC	  curves	  looking	  at	  specificity	  and	  
sensitivities	  of	  the	  individual	  target	  miRNAs	  compared	  to	  multiple	  miRNA	  measures.	  	  
	  
Target	  miRNA’s	  ability	  to	  predict	  TRG	  	  	  
In	  this	  study	  we	  did	  not	  find	  a	  statistical	  difference	  in	  target	  miRNA	  expression	  in	  plasma	  
in	  patients	  that	  responded	  to	  SCR	  or	  to	  LCCR.	  Again,	  it	  is	  likely	  that	  the	  small	  number	  of	  
patients	  have	  impacted	  on	  this	  finding.	  In	  a	  study	  by	  D’Angelo	  et	  al.	  (46),	  the	  authors	  
report	   11	   miRNA	   had	   differential	   expression	   in	   CRC	   patients	   when	   separated	   into	  
“responders”	   vs.	   “non-­‐responders”	   after	   LCCR	   therapy.	   In	   this	   retrospective	   study,	  
serum	  and	  tissue	  biopsies	  of	  tumour	  were	  obtained	  from	  rectal	  cancer	  patients	  prior	  to	  
neoadjuvant	   therapy	  being	   started.	   First	   looking	  at	  expression	   in	   tissue,	   the	  authors	  
identified	   11	   differentially	   expressed	   miRNA	   using	   microarray	   analysis	   on	   38	   tissue	  
samples	  (3	  patients	  had	  stage	  II	  disease,	  the	  rest	  had	  stage	  III).	  The	  authors	  focused	  on	  
miR-­‐125b,	  miR-­‐299-­‐5p	  and	  miR-­‐154,	  and	  in	  tissues	  they	  confirmed	  altered	  expression	  
which	   was	   statistically	   significant	   for	   all	   of	   these.	   The	   authors	   then	   reviewed	   the	  
expression	   in	   34	  patient’s	   serum,	   and	  again	   confirmed	  altered	  expression	  with	  miR-­‐
125b	   significantly	   increased	   in	   non-­‐responders	   (p	   =	   0.0087)	   which	   would	   allow	   for	  
predictive	  discrimination	  between	  the	  two	  groups	  (AUC	  0.782,	  95%	  CI	  0.6123-­‐0.9518).	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In	  a	  recently	  published	  study	  by	  Hiyoshi	  et	  al.	   (47),	  the	  authors	  report	  the	  predictive	  
capability	   of	   serum	   miR-­‐143	   in	   TRG	   response	   in	   rectal	   cancer	   patients.	   This	   was	   a	  
prospective	  study	  in	  which	  the	  authors	  selected	  18	  target	  miRNA	  to	  look	  for	  differential	  
expression.	  They	  collected	  94	  patients’	  serum	  in	  total,	  however	  it	  is	  unclear	  as	  to	  when	  
in	  the	  treatment	  this	  was	  collected.	  From	  those	  94	  samples,	  the	  authors	  selected	  13	  
patients	  with	  pCR	  and	  near	  pCR	  as	  “best”	  responders	  to	  LCCR,	  and	  12	  patients	  with	  no	  
response	   to	   LCCR	   as	   “worst”	   responders	   because	   it	   was	   thought	   that	   this	   would	  
highlight	   differences	   in	   expression	   between	   the	   groups	   the	   most.	   In	   the	   selected	  
subgroups	  the	  authors	  found	  that	  miR-­‐143	  and	  miR-­‐125b	  were	  differentially	  expressed,	  
but	  that	  when	  testing	  the	  complete	  group	  of	  94	  patients,	  only	  miR-­‐143	  had	  a	  statistically	  
significant	   difference	   between	   responders	   and	   non-­‐responders	   (p=	   0.004).	  
Interestingly,	  of	  an	  additional	  18	  miRNA	  that	  these	  authors	  specifically	  analysed,	  they	  
did	  not	  find	  significant	  differences	  in	  expression	  of	  miR-­‐145,	  miR-­‐21,	  and	  miR-­‐29a.	  They	  
did	  not	  find	  a	  significant	  decrease	  in	  miR-­‐125b	  as	  the	  previously	  mentioned	  study	  (46).	  
Of	   note	   this	   study	   did	   not	   have	   an	   endogenous	   control,	   which	   is	   important	   for	  
minimalising	  experimental	  error.	  Endogenous	  controls	  are	  important	  to	  normalise	  for	  
variation	  in	  starting	  material	  volumes,	  reaction	  efficiency	  and	  sample	  purity	  (80).	  The	  
authors	   did	   use	   cel-­‐miR-­‐39	   as	   an	   exogenous	   control.	   As	  mentioned	   previously,	   this	  
group	   looked	   at	   samples	   after	   neoadjuvant	   therapy	   prior	   to	   surgery	   in	   76	   of	   their	  
patients	  and	  found	  that	  miR-­‐143	  expression	  was	  significantly	  decreased	  after	  LCCR	  prior	  
to	  surgery.	  When	  separating	  out	  the	  patients	  into	  responders	  vs.	  non	  responders,	  they	  
found	  that	  serum	  miR-­‐143	  was	  only	  significantly	  altered	  in	  the	  non-­‐responder	  group.	  
This	  does	  raise	  the	  question	  of	  whether	  testing	  miRNA	  relative	  expression	  after	  LCCR	  
could	  help	  to	  determine	  whether	  or	  not	  a	  patient	  should	  proceed	  to	  surgery,	  and	  this	  
relates	   to	   our	   findings	   in	   that	   patients	   with	   an	   increased	   miR-­‐143	   after	   SCR	   could	  
indicate	  a	  therapeutic	  response	  to	  therapy.	  
	  
It	  is	  important	  to	  note	  that	  miR-­‐345	  has	  been	  reported	  to	  be	  differentially	  expressed	  in	  
LCCR	   responders	   vs	  non-­‐responders	  by	  Yu	  et	   al.	   (81).	   This	   group	   reviewed	  20	   tissue	  
samples	  post	  operatively	  (and	  post	  LCCR)	  and	  reviewed	  miRNA	  in	  their	  serum	  and	  found	  
a	   decrease	   in	   expression	   in	   the	   LCCR	   responders	   (p=0.002).	   Despite	   this,	   in	   our	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validation	  of	  our	  housekeeper	  miRNA,	  we	  found	  no	  difference	  in	  miR-­‐345	  expression	  
pre	  and	  post	  treatment.	  	  
	  
4.1	  Strengths	  and	  limitations	  
There	  were	  a	  number	  of	  strengths	  to	  this	  study	  including;	   its	  prospective	  design,	  the	  
use	  of	  both	  endogenous	  and	  exogenous	  controls,	  a	  group	  of	  well	  screened	  controls,	  and	  
using	  both	  SCR	  and	  LCCR	  patients.	  The	  limitations	  were	  mostly	  regarding	  small	  patient	  
numbers	  leading	  to	  a	  poorly	  powered	  study.	  	  
	  
There	  were	  clear	  benefits	  to	  the	  prospective	  nature	  in	  which	  the	  data	  was	  gathered.	  
First,	  plasma	  obtained	  before	  and	  after	  treatment	  allowed	  for	  the	  assessment	  of	  paired	  
samples	   for	  miRNA	   levels	  pre	  and	  post	  neoadjuvant	   therapy.	  We	  had	   the	  benefit	  of	  
standardised	   blood	   collection	   with	   high	   quality	   specimens	   which	   were	   processed	  
quickly.	  It	  also	  allowed	  for	  the	  collection	  of	  demographic	  data	  and	  other	  clinically	  useful	  
tests	  such	  as	  CRP,	  CEA,	  and	  NLR	  which	  could	  then	  be	  correlated	  with	  miRNA	  levels.	  Data	  
on	   these	   correlations	   is	   lacking	   and	   therefore	  we	  will	   be	   able	   to	   add	   to	   the	  pool	  of	  
research	  in	  this	  area	  (42).	  In	  addition	  to	  this,	  patients	  in	  the	  biobank	  will	  have	  further	  
blood	   samples	   obtained	   and	   can	   be	   followed	   for	   outcomes	   such	   as	   either	   local	  
recurrence,	  rates	  of	  metastatic	  disease,	  or	  disease	  free	  survival.	  	  	  
	  
Regarding	  standardisation	  of	  RT-­‐qPCR,	  this	  study	  used	  both	  endogenous	  and	  exogenous	  
controls	  as	  housekeepers.	  cel-­‐miR-­‐39	  is	  a	  reliable	  exogenous	  control	  to	  ensure	  accurate	  
extraction	  efficiency.	  miR-­‐345	  has	  been	  reported	  to	  be	  stable	  in	  plasma	  and	  to	  have	  the	  
same	   expression	   in	   CRC	   patients	   vs	   controls	   in	   tissue,	   plasma,	   and	   exosomes	   (53),	  
except	   as	  noted	   in	   the	   	   study	  mentioned	  previously	  by	   Yu	  et	   al.	   (81).	   There	  was	  no	  
difference	   between	   miR-­‐345	   or	   cel-­‐miR-­‐39	   Ct	   values	   in	   control	   patients	   vs.	   cancer	  
patients	   or	   in	   cancer	   patients	   pre	   vs.	   post	   neoadjuvant	   therapy	   and	   therefore	   we	  
consider	  both	  of	  these	  to	  be	  adequate	  controls	  for	  the	  present	  study.	  We	  used	  both	  
miR-­‐345	   and	   cel-­‐m-­‐39	   because	   there	   are	   still	   very	   few	   reports	   that	   detail	   robust	  
identification	  and	  validations	   strategy	   for	   suitable	   reference	  genes	   for	  normalisation	  
	   55	  
(82),	   despite	   reliable	   controls	   being	   important	   for	   the	   reliability	   and	   accuracy	   of	  
circulating	  miRNA	  biomarker	  research	  (83).	  	  
	  
Short	  course	  radiation	  neoadjuvant	  therapy	  is	  not	  often	  considered	  in	  predictive	  miRNA	  
studies.	   This	   is	   likely	   because	   it	   is	   unusual	   to	   see	   a	   significant	   amount	   of	   tumour	  
regression	  when	  the	  time	  to	  surgery	  after	  radiation	  is	  short.	  It	  is	  therefore	  an	  interesting	  
finding	   that	   miR-­‐143	   has	   increased	   after	   SCR	   therapy.	   The	   Stockholm	   III	   trial	   has	  
demonstrated	  that	  a	  delay	  to	  surgery	  after	  SCR	  can	  lead	  to	  increased	  tumour	  regression	  
with	  statistically	  significant	  higher	  rates	  of	  pCR	  and	  Dworak	  grade	  4	  regression	  (73).	  In	  
this	  study,	  we	  looked	  at	  time	  to	  surgery	  after	  neoadjuvant	  therapy	  ended	  to	  see	  if	  any	  
delays	  had	  confounded	  our	  results.	  It	  would	  also	  be	  interesting	  to	  compare	  post	  SCR	  
levels	  with	  post	  surgical	  levels	  and	  see	  if	  they	  decrease	  dramatically.	  	  
	  
A	   clear	   limitation	   to	   this	   study	   is	   the	   small	  data	   set.	   This	   is	  due	   to	   the	   frequency	  of	  
patients	   presenting	   with	   rectal	   cancer	   requiring	   neoadjuvant	   therapy	   at	  Wellington	  
Hospital.	  Waiting	  for	  long	  course	  treatment	  then	  the	  stand	  down	  period	  prior	  to	  surgery	  
has	   allowed	   for	   this	   sample	   size.	   Having	  more	   patients	   and	   therefore	  more	   plasma	  
samples	  will	  be	  beneficial	  in	  that	  it	  will	  reflect	  the	  natural	  heterogeneity	  of	  the	  disease	  
(42).	  Having	  said	  this,	  previous	  publications	  do	  have	  smaller	  or	  similar	  data	  sizes	  (46)	  
and	  this	  is	  a	  pilot	  study.	  	  
	  
Importantly,	   another	   limitation	   was	   that	   we	   did	   not	   have	   any	   patients	   with	   pCR.	  
Unfortunately,	   this	   is	   not	   something	   that	   could	   have	   been	   altered	   and	   is	   likely	   a	  
reflection	  of	   this	  being	  a	  small	  study.	  This	  could	  mean	  that	  our	  samples	  are	   likely	  to	  
reflect	  a	   subtler	  phenotype	  difference	   than	   the	  other	   studies	  we	  are	  comparing	  our	  
results	  too.	  	  
	  
In	  this	  study	  we	  have	  used	  a	  hypothesis	  driven	  approach	  rather	  than	  discovery	  driven	  
approach.	  Therefore,	  we	  have	  analysed	  expression	  of	  only	  four	  target	  miRNA’s.	  It	  would	  
be	  ideal	  to	  have	  performed	  microarray	  or	  deep	  sequencing	  to	  “discover”	  which	  miRNA	  
had	  altered	  expression	  first	  but	  we	  have	  used	  this	  study	  design	  due	  to	  available	  time	  
and	  resources.	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Regarding	   patient	   outcomes,	   what	   is	   most	   clinically	   applicable	   to	   the	   patients	  
undergoing	  SCR	  is	  local	  recurrence.	  In	  this	  study	  we	  have	  used	  TRG	  as	  a	  surrogate	  for	  
recurrence	   due	   to	   the	   reasonably	   short	   length	   of	   time	   that	   the	   biobank	   has	   been	  
operating.	  It	  is	  interesting	  that	  circulating	  miR-­‐29c	  has	  been	  reported	  to	  be	  increased	  in	  
patients	  who	   have	   early	   recurrence	  within	   one	   year	   of	   surgery	   (p	   =	   0.012)	   (84).	   As	  
patient	  follow	  up	  continues,	  recurrence	  data	  will	  be	  available	  to	  be	  analysed.	  
	  
4.2	  Future	  directions	  
The	   target	   miRNA	   we	   have	   chosen	   have	   not	   yet	   shown	   statistically	   significant	  
differences	   in	   our	   patient	   population	   in	   plasma	   regarding	   predicting	   TRG.	   I	   would	  
continue	  to	  investigate	  these	  target	  miRNA	  in	  a	  larger	  patient	  population.	  	  
	  
With	   the	   samples	  we	   are	   collecting	   for	   the	  CRC	  biobank,	  we	  will	   be	   able	   to	   look	   at	  
recurrence	  rates	  and	  survival	  outcomes	  with	  this	  patient	  group	  and	  see	  if	  there	  is	  any	  
correlation	  with	  our	  target	  miRNA	  expression	   levels.	   It	   is	  possible	  that	  there	   is	  some	  
clinical	  significance	  to	  the	  change	  in	  miRNA-­‐143	  after	  therapy.	  As	  previously	  stated	  it	  
would	  be	   interesting	  to	  further	  analyse	  this	  group	  to	  see	  what	  the	  outcomes	  are	  for	  
these	  patients	  clinically.	  	  
	  
Given	  promising	  findings	  with	  miRNA	  in	  serum,	  further	  work	  should	  be	  focused	  on	  blood	  
based	  biomarkers	  where	  possible.	  	  
	  
4.3	  Overall	  significance	  	  
New	  Zealand	  has	  a	  high	   incidence	  of	  CRC	  by	   international	  standards,	  with	  over	  1200	  
deaths	  annually	   (7).	   Specifically,	   rectal	   cancer	  contributes	   to	  a	   significant	  proportion	  
(25%)	  of	  these	  cases	  (7).	  Despite	  advances	  in	  the	  detection	  and	  surgical	  management	  
of	   rectal	   cancer,	   we	   still	   lack	   the	   ability	   to	   predict	   which	   patients	   will	   respond	   to	  
neoadjuvant	  therapy.	  This	  thesis	  has	  examined	  the	  levels	  of	  miR-­‐21,	  miR-­‐29a,	  miR-­‐145	  
and	  miR-­‐143	  in	  plasma	  in	  patients	  with	  rectal	  cancer	  undergoing	  neoadjuvant	  therapy.	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This	  is	  the	  first	  study	  to	  use	  patients’	  plasma	  to	  evaluate	  the	  expression	  of	  these	  miRNA	  
and	  examine	  if	  this	  is	  related	  to	  TRG.	  This	  is	  important	  because	  blood	  based	  biomarkers	  
are	   a	  much	  more	   accessible	   and	  potentially	   clinically	   useful	   tool	   for	   prediction	   than	  
tumour	  biopsy.	  Findings	  from	  this	  study	  will	  contribute	  to	  the	  pool	  of	  research	  on	  the	  
use	   of	   miRNA’s	   in	   CRC	   for	   diagnostic	   and	   predictive	   tests.	   Future	   samples	   being	  
collected	  from	  these	  patients	  may	  also	  contribute	  to	  knowledge	  on	  recurrence.	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